Skip to main content
Psychedex
Sources
28
1 strong · 16 moderate · 11 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
74
52verified2partial19inconclusive1not supported

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
May 7, 2026 · pipeline-v5
Values approved
212/212 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold30 mg30 mglow
Low30–60 mg30–60 mglow
Common60–100 mg60–100 mglow
Strong100–130 mg100–130 mglow
Heavy130+ mg130+ mglow
Editorial

Carried forward from existing DB / community consensus (PsychonautWiki). No published clinical dose-finding data for HXE. Broadly consistent with community reports. HXE is ~2× more potent than MXE at NMDAR (IC₅₀ 0.227 vs 0.524 µM, Irie et al. 2022), which is reflected in these lower ranges relative to MXE.

Reasoning

Carried forward from existing DB / community consensus (PsychonautWiki). No published clinical dose-finding data for HXE. Broadly consistent with community reports. HXE is ~2× more potent than MXE at NMDAR (IC₅₀ 0.227 vs 0.524 µM, Irie et al. 2022), which is reflected in these lower ranges relative to MXE.

Evidence basis: community_consensus_large

sublingualtrace

FieldPublishedAI ProposedConfidence
Threshold30 mg30 mglow
Low30–60 mg30–60 mglow
Common60–100 mg60–100 mglow
Strong100–130 mg100–130 mglow
Heavy130+ mg130+ mglow
Editorial

Carried forward from existing DB / community consensus. Sublingual ranges are identical to oral in seed data, which is atypical — sublingual administration usually has higher bioavailability, suggesting these ranges may be too high. Flagged for reviewer. No published sublingual bioavailability data for HXE.

Reasoning

Carried forward from existing DB / community consensus. Sublingual ranges are identical to oral in seed data, which is atypical — sublingual administration usually has higher bioavailability, suggesting these ranges may be too high. Flagged for reviewer. No published sublingual bioavailability data for HXE.

Evidence basis: community_consensus_large

insufflatedtrace

FieldPublishedAI ProposedConfidence
Threshold20 mg20 mglow
Low20–40 mg20–40 mglow
Common40–70 mg40–70 mglow
Strong70–120 mg70–120 mglow
Heavy120+ mg120+ mglow
Editorial

Carried forward from existing DB / community consensus (PsychonautWiki). Lower ranges than oral reflect expected higher nasal bioavailability. No published dose-finding data for insufflated HXE.

Reasoning

Carried forward from existing DB / community consensus (PsychonautWiki). Lower ranges than oral reflect expected higher nasal bioavailability. No published dose-finding data for insufflated HXE.

Evidence basis: community_consensus_large

Duration

oral

FieldPublishedAI ProposedConfidence
Come uptrace30–60 minutes30–60 minuteslow
Editorial

Existing DB / community consensus. No published data.

Reasoning

Existing DB / community consensus. No published data.

Evidence basis: community_consensus_large

Offsettrace3–6 hours3–6 hourslow
Editorial

Existing DB / community consensus. Extended offset consistent with arylcyclohexylamine class.

Reasoning

Existing DB / community consensus. Extended offset consistent with arylcyclohexylamine class.

Evidence basis: community_consensus_large

Onsettrace20–60 minutes20–60 minuteslow
Editorial

Existing DB / community consensus. Consistent with MXE's longer-than-ketamine onset. No published PK data for oral HXE.

Reasoning

Existing DB / community consensus. Consistent with MXE's longer-than-ketamine onset. No published PK data for oral HXE.

Evidence basis: community_consensus_large

Peaktrace2–4 hours2–4 hourslow
Editorial

Existing DB / community consensus. Consistent with MXE duration profile (Horsley et al. 2016).

Reasoning

Existing DB / community consensus. Consistent with MXE duration profile (Horsley et al. 2016).

Evidence basis: community_consensus_large

Totaltrace3–8 hours3–8 hourslow
Editorial

Existing DB / community consensus. 3-8 hour range consistent with article prose and MXE's longer-than-ketamine duration.

Reasoning

Existing DB / community consensus. 3-8 hour range consistent with article prose and MXE's longer-than-ketamine duration.

Evidence basis: community_consensus_large

After effectstrace1–12 hours1–12 hourslow
Editorial

Existing DB / community consensus. Wide range reflects individual variability.

Reasoning

Existing DB / community consensus. Wide range reflects individual variability.

Evidence basis: community_consensus_large

sublingual

FieldPublishedAI ProposedConfidence
Onsettrace20–60 minutes20–60 minuteslow
Editorial

Existing DB / community consensus. Similar to oral onset per seed data.

Reasoning

Existing DB / community consensus. Similar to oral onset per seed data.

Evidence basis: community_consensus_large

Peaktrace2–4 hours2–4 hourslow
Editorial

Existing DB / community consensus.

Reasoning

Existing DB / community consensus.

Evidence basis: community_consensus_large

Totaltrace3–6 hours3–6 hourslow
Editorial

Existing DB / community consensus.

Reasoning

Existing DB / community consensus.

Evidence basis: community_consensus_large

Come uptrace30–60 minutes30–60 minuteslow
Editorial

Existing DB / community consensus.

Reasoning

Existing DB / community consensus.

Evidence basis: community_consensus_large

Offsettrace2–6 hours2–6 hourslow
Editorial

Existing DB / community consensus.

Reasoning

Existing DB / community consensus.

Evidence basis: community_consensus_large

After effectstrace1–12 hours1–12 hourslow
Editorial

Existing DB / community consensus.

Reasoning

Existing DB / community consensus.

Evidence basis: community_consensus_large

insufflated

FieldPublishedAI ProposedConfidence
Come uptrace20–40 minutes20–40 minuteslow
Editorial

Existing DB / community consensus.

Reasoning

Existing DB / community consensus.

Evidence basis: community_consensus_large

Peaktrace1.5–4 hours1.5–4 hourslow
Editorial

Existing DB / community consensus.

Reasoning

Existing DB / community consensus.

Evidence basis: community_consensus_large

Totaltrace3–6 hours3–6 hourslow
Editorial

Existing DB / community consensus.

Reasoning

Existing DB / community consensus.

Evidence basis: community_consensus_large

After effectstrace2–7 hours2–7 hourslow
Editorial

Existing DB / community consensus.

Reasoning

Existing DB / community consensus.

Evidence basis: community_consensus_large

Onsettrace10–30 minutes10–30 minuteslow
Editorial

Existing DB / community consensus. Faster onset than oral reflects nasal absorption.

Reasoning

Existing DB / community consensus. Faster onset than oral reflects nasal absorption.

Evidence basis: community_consensus_large

Offsettrace2–4 hours2–4 hourslow
Editorial

Existing DB / community consensus.

Reasoning

Existing DB / community consensus.

Evidence basis: community_consensus_large

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutemoderatemoderatelow
Chronicmoderatemoderatelow
Organs Affectedneurological, urological, hepatic, renal, cardiovascularneurological, urological, hepatic, renal, cardiovascularlow
Editorial

Moderate acute/chronic ratings are class-inferred from MXE (fatal cases with hepatic/renal failure, cerebellar toxicity) and ketamine (chronic cystitis). Evidence discount applied: raw findings from MXE case series would suggest moderate-to-high, discounted one level for structural analogy but retained at moderate given CFSRE death-link. All organ systems from work-notes.

Reasoning

Moderate acute/chronic ratings are class-inferred from MXE (fatal cases with hepatic/renal failure, cerebellar toxicity) and ketamine (chronic cystitis). Evidence discount applied: raw findings from MXE case series would suggest moderate-to-high, discounted one level for structural analogy but retained at moderate given CFSRE death-link. All organ systems from work-notes.

Evidence basis: structural_analogy

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicallowlowlow
Psychologicalmoderatemoderatelow
Compulsive Redosingmoderatemoderatelow
Dose Escalationmoderatemoderatelow
Editorial

All dependence values inferred from ketamine (Pal et al. 2002) and MXE (Botanas et al. 2019) class pharmacology. Physical dependence lowered from seed 'moderate' to 'low' per work-notes — ketamine dependence lacks prominent physical withdrawal. Psychological dependence retained at moderate given established mesolimbic dopamine mechanism.

Reasoning

All dependence values inferred from ketamine (Pal et al. 2002) and MXE (Botanas et al. 2019) class pharmacology. Physical dependence lowered from seed 'moderate' to 'low' per work-notes — ketamine dependence lacks prominent physical withdrawal. Psychological dependence retained at moderate given established mesolimbic dopamine mechanism.

Evidence basis: structural_analogy

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitynonenonelow
Symptomscraving, dysphoria, anhedonia, cognitive impairmentcraving, dysphoria, anhedonia, cognitive impairmentlow
FatalNoNolow
Medical SupervisionNot requiredNot requiredlow
Editorial

Ketamine-class dependence is characterized by tolerance and craving without a prominent physical withdrawal syndrome at typical use levels. No HXE-specific withdrawal data exist. Symptoms listed are psychological sequelae of cessation observed in ketamine-dependent populations, not a formal withdrawal syndrome.

Reasoning

Ketamine-class dependence is characterized by tolerance and craving without a prominent physical withdrawal syndrome at typical use levels. No HXE-specific withdrawal data exist. Symptoms listed are psychological sequelae of cessation observed in ketamine-dependent populations, not a formal withdrawal syndrome.

Evidence basis: structural_analogy

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Buildupmoderatemoderatelow
Half-life5 days5 dayslow
Full Reset1.5 weeks1.5 weekslow
Cross-tolerancesketamine, methoxetamine, PCP, dextromethorphan, deschloroketamineketamine, methoxetamine, PCP, dextromethorphan, deschloroketaminelow
Editorial

All tolerance parameters from community consensus (PsychonautWiki) carried forward from seed data. Mechanism inferred from ketamine research (Zanos et al. 2018). No HXE-specific tolerance studies exist. Half-life and reset values are unverified against any published source.

Reasoning

All tolerance parameters from community consensus (PsychonautWiki) carried forward from seed data. Mechanism inferred from ketamine research (Zanos et al. 2018). No HXE-specific tolerance studies exist. Half-life and reset values are unverified against any published source.

Evidence basis: community_consensus_large

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
hepatic Hepatic impairmenttraceabsoluteabsolutelow
Editorial

Class-inferred from fatal MXE case (Wiergowski et al. 2014) documenting hepatic failure. No HXE-specific hepatotoxicity data exist.

Reasoning

Class-inferred from fatal MXE case (Wiergowski et al. 2014) documenting hepatic failure. No HXE-specific hepatotoxicity data exist.

renal Renal impairmenttraceabsoluteabsolutelow
Editorial

Class-inferred from fatal MXE case (Wiergowski et al. 2014) documenting acute renal failure. No HXE-specific renal toxicity data exist.

Reasoning

Class-inferred from fatal MXE case (Wiergowski et al. 2014) documenting acute renal failure. No HXE-specific renal toxicity data exist.

other Bladder or urological conditionstraceabsoluteabsolutelow
Editorial

Ketamine-associated cystitis is well-documented (Chen et al. 2011, Lai et al. 2012, Shen et al. 2016). Risk extrapolated to HXE from shared arylcyclohexylamine class. No HXE-specific bladder data.

Reasoning

Ketamine-associated cystitis is well-documented (Chen et al. 2011, Lai et al. 2012, Shen et al. 2016). Risk extrapolated to HXE from shared arylcyclohexylamine class. No HXE-specific bladder data.

psychiatric Personal or family history of psychotic disorderstraceabsoluteabsolutemedium
Editorial

Class-level evidence is strong: NMDAR antagonists are established psychotomimetics used to model schizophrenia preclinically (Zanos et al. 2018). No HXE-specific psychiatric case data, but mechanism is well-established.

Reasoning

Class-level evidence is strong: NMDAR antagonists are established psychotomimetics used to model schizophrenia preclinically (Zanos et al. 2018). No HXE-specific psychiatric case data, but mechanism is well-established.

other Concurrent MAOI usetraceabsoluteabsolutelow
Editorial

Inferred from MXE SERT affinity (Roth et al. 2013) and MXE serotonergic effects (Marti et al. 2021). No HXE-specific serotonergic data. Precautionary absolute contraindication.

Reasoning

Inferred from MXE SERT affinity (Roth et al. 2013) and MXE serotonergic effects (Marti et al. 2021). No HXE-specific serotonergic data. Precautionary absolute contraindication.

cardiovascular Cardiovascular diseasetracerelativerelativelow
Editorial

Class-inferred from ketamine sympathomimetic profile and MXE case report (Imbert et al. 2014) showing ST-elevation. No HXE-specific cardiovascular data.

Reasoning

Class-inferred from ketamine sympathomimetic profile and MXE case report (Imbert et al. 2014) showing ST-elevation. No HXE-specific cardiovascular data.

pregnancy breastfeeding Pregnancytraceabsoluteabsolutelow
Editorial

Precautionary contraindication based on established role of NMDAR in neurodevelopment. No HXE-specific reproductive data.

Reasoning

Precautionary contraindication based on established role of NMDAR in neurodevelopment. No HXE-specific reproductive data.

respiratory Concurrent CNS depressant usetracerelativerelativemedium
Editorial

Class-level interaction well-established for ketamine. Additive CNS depression with depressants is a pharmacological certainty for NMDAR antagonists with sedative properties.

Reasoning

Class-level interaction well-established for ketamine. Additive CNS depression with depressants is a pharmacological certainty for NMDAR antagonists with sedative properties.

other Concurrent stimulant usetracerelativerelativemedium
Editorial

Directly supported by fatal MXE+amphetamine case (Wiergowski et al. 2014). The strongest evidence-based interaction warning for this class.

Reasoning

Directly supported by fatal MXE+amphetamine case (Wiergowski et al. 2014). The strongest evidence-based interaction warning for this class.

Timeline Phases

insufflated

FieldPublishedAI ProposedConfidence
Resolutiontrace7200–14400 sec(i=0.35)7200–14400 sec(i=0.35)low
Editorial

All timeline phases from community consensus and existing DB seed data. Insufflated onset is faster with sharper peak than oral. Duration profile consistent with community reports. No published human PK data for insufflated HXE.

Reasoning

All timeline phases from community consensus and existing DB seed data. Insufflated onset is faster with sharper peak than oral. Duration profile consistent with community reports. No published human PK data for insufflated HXE.

Evidence basis: community_consensus_large

Afterglowtrace7200–25200 sec(i=0.10)7200–25200 sec(i=0.10)low
Editorial

All timeline phases from community consensus and existing DB seed data. Insufflated onset is faster with sharper peak than oral. Duration profile consistent with community reports. No published human PK data for insufflated HXE.

Reasoning

All timeline phases from community consensus and existing DB seed data. Insufflated onset is faster with sharper peak than oral. Duration profile consistent with community reports. No published human PK data for insufflated HXE.

Evidence basis: community_consensus_large

Onsettrace600–1800 sec(i=0.15)600–1800 sec(i=0.15)low
Editorial

All timeline phases from community consensus and existing DB seed data. Insufflated onset is faster with sharper peak than oral. Duration profile consistent with community reports. No published human PK data for insufflated HXE.

Reasoning

All timeline phases from community consensus and existing DB seed data. Insufflated onset is faster with sharper peak than oral. Duration profile consistent with community reports. No published human PK data for insufflated HXE.

Evidence basis: community_consensus_large

Come uptrace1200–2700 sec(i=0.50)1200–2700 sec(i=0.50)low
Editorial

All timeline phases from community consensus and existing DB seed data. Insufflated onset is faster with sharper peak than oral. Duration profile consistent with community reports. No published human PK data for insufflated HXE.

Reasoning

All timeline phases from community consensus and existing DB seed data. Insufflated onset is faster with sharper peak than oral. Duration profile consistent with community reports. No published human PK data for insufflated HXE.

Evidence basis: community_consensus_large

Peaktrace5400–14400 sec(i=1.00)5400–14400 sec(i=1.00)low
Editorial

All timeline phases from community consensus and existing DB seed data. Insufflated onset is faster with sharper peak than oral. Duration profile consistent with community reports. No published human PK data for insufflated HXE.

Reasoning

All timeline phases from community consensus and existing DB seed data. Insufflated onset is faster with sharper peak than oral. Duration profile consistent with community reports. No published human PK data for insufflated HXE.

Evidence basis: community_consensus_large

oral

FieldPublishedAI ProposedConfidence
Resolutiontrace10800–21600 sec(i=0.40)10800–21600 sec(i=0.40)low
Editorial

All timeline phases from community consensus (PsychonautWiki) and existing DB seed data. Duration profile consistent with MXE's longer-than-ketamine time course (Horsley et al. 2016). No published human PK data for oral HXE. Intensity weights from work-notes.

Reasoning

All timeline phases from community consensus (PsychonautWiki) and existing DB seed data. Duration profile consistent with MXE's longer-than-ketamine time course (Horsley et al. 2016). No published human PK data for oral HXE. Intensity weights from work-notes.

Evidence basis: community_consensus_large

Onsettrace1200–3600 sec(i=0.10)1200–3600 sec(i=0.10)low
Editorial

All timeline phases from community consensus (PsychonautWiki) and existing DB seed data. Duration profile consistent with MXE's longer-than-ketamine time course (Horsley et al. 2016). No published human PK data for oral HXE. Intensity weights from work-notes.

Reasoning

All timeline phases from community consensus (PsychonautWiki) and existing DB seed data. Duration profile consistent with MXE's longer-than-ketamine time course (Horsley et al. 2016). No published human PK data for oral HXE. Intensity weights from work-notes.

Evidence basis: community_consensus_large

Come uptrace1800–3600 sec(i=0.40)1800–3600 sec(i=0.40)low
Editorial

All timeline phases from community consensus (PsychonautWiki) and existing DB seed data. Duration profile consistent with MXE's longer-than-ketamine time course (Horsley et al. 2016). No published human PK data for oral HXE. Intensity weights from work-notes.

Reasoning

All timeline phases from community consensus (PsychonautWiki) and existing DB seed data. Duration profile consistent with MXE's longer-than-ketamine time course (Horsley et al. 2016). No published human PK data for oral HXE. Intensity weights from work-notes.

Evidence basis: community_consensus_large

Peaktrace7200–14400 sec(i=1.00)7200–14400 sec(i=1.00)low
Editorial

All timeline phases from community consensus (PsychonautWiki) and existing DB seed data. Duration profile consistent with MXE's longer-than-ketamine time course (Horsley et al. 2016). No published human PK data for oral HXE. Intensity weights from work-notes.

Reasoning

All timeline phases from community consensus (PsychonautWiki) and existing DB seed data. Duration profile consistent with MXE's longer-than-ketamine time course (Horsley et al. 2016). No published human PK data for oral HXE. Intensity weights from work-notes.

Evidence basis: community_consensus_large

Afterglowtrace3600–43200 sec(i=0.10)3600–43200 sec(i=0.10)low
Editorial

All timeline phases from community consensus (PsychonautWiki) and existing DB seed data. Duration profile consistent with MXE's longer-than-ketamine time course (Horsley et al. 2016). No published human PK data for oral HXE. Intensity weights from work-notes.

Reasoning

All timeline phases from community consensus (PsychonautWiki) and existing DB seed data. Duration profile consistent with MXE's longer-than-ketamine time course (Horsley et al. 2016). No published human PK data for oral HXE. Intensity weights from work-notes.

Evidence basis: community_consensus_large

sublingual

FieldPublishedAI ProposedConfidence
Onsettrace1200–3600 sec(i=0.10)1200–3600 sec(i=0.10)low
Editorial

All timeline phases from community consensus and existing DB seed data. Sublingual profile mirrors oral in seed data, which is atypical — sublingual usually has higher bioavailability suggesting these durations may overestimate. No published data for sublingual HXE.

Reasoning

All timeline phases from community consensus and existing DB seed data. Sublingual profile mirrors oral in seed data, which is atypical — sublingual usually has higher bioavailability suggesting these durations may overestimate. No published data for sublingual HXE.

Evidence basis: community_consensus_large

Come uptrace1800–3600 sec(i=0.40)1800–3600 sec(i=0.40)low
Editorial

All timeline phases from community consensus and existing DB seed data. Sublingual profile mirrors oral in seed data, which is atypical — sublingual usually has higher bioavailability suggesting these durations may overestimate. No published data for sublingual HXE.

Reasoning

All timeline phases from community consensus and existing DB seed data. Sublingual profile mirrors oral in seed data, which is atypical — sublingual usually has higher bioavailability suggesting these durations may overestimate. No published data for sublingual HXE.

Evidence basis: community_consensus_large

Peaktrace7200–14400 sec(i=1.00)7200–14400 sec(i=1.00)low
Editorial

All timeline phases from community consensus and existing DB seed data. Sublingual profile mirrors oral in seed data, which is atypical — sublingual usually has higher bioavailability suggesting these durations may overestimate. No published data for sublingual HXE.

Reasoning

All timeline phases from community consensus and existing DB seed data. Sublingual profile mirrors oral in seed data, which is atypical — sublingual usually has higher bioavailability suggesting these durations may overestimate. No published data for sublingual HXE.

Evidence basis: community_consensus_large

Resolutiontrace7200–21600 sec(i=0.40)7200–21600 sec(i=0.40)low
Editorial

All timeline phases from community consensus and existing DB seed data. Sublingual profile mirrors oral in seed data, which is atypical — sublingual usually has higher bioavailability suggesting these durations may overestimate. No published data for sublingual HXE.

Reasoning

All timeline phases from community consensus and existing DB seed data. Sublingual profile mirrors oral in seed data, which is atypical — sublingual usually has higher bioavailability suggesting these durations may overestimate. No published data for sublingual HXE.

Evidence basis: community_consensus_large

Afterglowtrace3600–43200 sec(i=0.10)3600–43200 sec(i=0.10)low
Editorial

All timeline phases from community consensus and existing DB seed data. Sublingual profile mirrors oral in seed data, which is atypical — sublingual usually has higher bioavailability suggesting these durations may overestimate. No published data for sublingual HXE.

Reasoning

All timeline phases from community consensus and existing DB seed data. Sublingual profile mirrors oral in seed data, which is atypical — sublingual usually has higher bioavailability suggesting these durations may overestimate. No published data for sublingual HXE.

Evidence basis: community_consensus_large

Dose Tier Summaries

thresholdtrace
low

A barely perceptible alteration in sensory processing emerges — subtle bodily lightness, a faint mood lift, and a gentle proprioceptive shift that signals the compound's presence without producing overt dissociation. Cognitive function remains largely intact, and the user may question whether effects are placebo. Physically, a mild warmth or tingling may be noticed, particularly in the extremities. There is no meaningful motor control impairment, nausea, or sedation at this level. Effects at threshold may be imperceptible to users without prior dissociative experience. The duration commitment is the same as higher tiers (3–8 hours oral), making threshold doses a poor choice for those seeking brief experiences.

Editorial

Work-notes threshold outline expanded with substance-specific texture from prose and research. All effects inferred from arylcyclohexylamine class pharmacology and community consensus; no HXE-specific threshold data published.

Reasoning

Work-notes threshold outline expanded with substance-specific texture from prose and research. All effects inferred from arylcyclohexylamine class pharmacology and community consensus; no HXE-specific threshold data published.

Evidence basis: community_consensus_large

lighttrace
low

Mild dissociation becomes apparent — a gentle sense of detachment from the body accompanied by a warm body high and subtle analgesic warmth. Music enhancement is noticeable, sounds acquiring a richer, more immersive quality. Cognitive effects emerge as mild thought deceleration and initial derealization, though coherent conversation remains possible. Physically, mild motor control impairment manifests as slightly unsteady gait. Some users report gentle stimulation rather than sedation at this level. Nausea is uncommon but possible, particularly with insufflated administration. A faint numbness in the extremities reflects the compound's analgesic properties. Social interaction is still manageable but attention may drift. Light doses are often described as having a warm, contemplative character distinct from the more stimulating profile of methoxy-substituted analogs.

Editorial

Work-notes light tier outline expanded. Community reports describe warm, analgesic quality attributed to 3-OH substitution. Motor impairment and music enhancement from seed effect profile. No published clinical data.

Reasoning

Work-notes light tier outline expanded. Community reports describe warm, analgesic quality attributed to 3-OH substitution. Motor impairment and music enhancement from seed effect profile. No published clinical data.

Evidence basis: community_consensus_large

commontrace
low

A clear dissociative state establishes itself — pronounced derealization and depersonalization create a sense of observing experience from a comfortable distance. Cognitive euphoria is prominent, accompanied by introspective depth and immersion enhancement. Visual processing suppression and spatial disorientation become obvious, and internal focus deepens substantially. Analgesic effects are now clearly apparent, with significant touch suppression and pain suppression. Motor control impairment is meaningful — walking requires deliberate effort and coordination is noticeably degraded. Sedation predominates over stimulation at this level. Dizziness and mild nausea may occur, particularly during the come-up. Memory suppression begins to affect recall of the experience. Time alteration distorts the subjective passage of time. This tier represents the core dissociative experience for most users — deeply introspective and perceptually altered, but with retained awareness of external surroundings.

Editorial

Work-notes common tier outline expanded with effects profile values (derealization 0.65, depersonalization 0.6, cognitive euphoria 0.6, motor impairment 0.6, pain suppression 0.65, memory suppression 0.55). Community consensus basis.

Reasoning

Work-notes common tier outline expanded with effects profile values (derealization 0.65, depersonalization 0.6, cognitive euphoria 0.6, motor impairment 0.6, pain suppression 0.65, memory suppression 0.55). Community consensus basis.

Evidence basis: community_consensus_large

strongtrace
low

Deep dissociation approaches 'hole' territory — a profound cognitive disconnection from ordinary waking consciousness. Ego dissolution onset may occur, with the boundary between self and environment becoming uncertain. Vivid internal hallucinations emerge, ranging from abstract geometric patterns to fully immersive dreamlike scenarios. External awareness is greatly reduced. Motor control is severely impaired — standing and walking become unreliable or impossible. Pain suppression is profound. Sedation is dominant. Nystagmus (eye wobbles) may be pronounced. Memory suppression is significant, and recall of the peak experience may be fragmentary. Analysis suppression and thought deceleration are deep at this tier. Pattern recognition suppression and visual acuity suppression are prominent. The experience is intensely introspective and may carry existential weight. Users should be in a safe, supervised environment with no need to move or respond to external demands.

Editorial

Work-notes strong tier outline expanded. Ego dissolution (0.4 intensity at common) intensifies at strong doses. Internal hallucinations, severe motor impairment, and memory suppression from effects profile. Class pharmacology and community reports.

Reasoning

Work-notes strong tier outline expanded. Ego dissolution (0.4 intensity at common) intensifies at strong doses. Internal hallucinations, severe motor impairment, and memory suppression from effects profile. Class pharmacology and community reports.

Evidence basis: community_consensus_large

heavytrace
low

A full dissociative hole — complete disconnection from external reality and the ordinary sense of self. Ego dissolution is likely total, and the experience may include entity contact, death-rebirth sequences, or near-death experience phenomenology. The distinction between internal and external reality dissolves entirely. Noetic insight and existential realization may occur with lasting psychological impact. Total motor incapacitation is expected — the user is functionally unconscious to external observation while experiencing vivid internal states. Amnesia for the peak experience is likely. Respiratory depression risk increases, particularly if combined with any CNS depressant. HXE is approximately twice as potent as MXE at the NMDA receptor (IC₅₀ 0.227 vs 0.524 µM). Users transitioning from MXE should halve their expected dose. The 3–8 hour oral duration means commitment to a heavy experience is substantially longer than a ketamine hole (1–2 hours). A sober sitter is essential. Do not combine with any other substance.

Editorial

Work-notes heavy tier outline expanded with substance-specific safety notes. Potency comparison from Irie et al. 2022. Duration comparison from community data. All effects class-inferred from arylcyclohexylamine pharmacology.

Reasoning

Work-notes heavy tier outline expanded with substance-specific safety notes. Potency comparison from Irie et al. 2022. Duration comparison from community data. All effects class-inferred from arylcyclohexylamine pharmacology.

Evidence basis: community_consensus_large

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

1 strong · 16 moderate · 11 weak
  1. [1]
    moderate
    Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors
    Irie T, Yanase Y, Demizu Y, Usami M, Kikura-Hanajiri R · 2022 · Journal of Pharmacological Sciences
    doi.org/10.1016/j.jphs.2022.09.005pubmed 3634404511 claims checked7 verified4 inconclusive
  2. [2]
    moderate
    Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn
    Meyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH · 2013 · Analytical and Bioanalytical Chemistry
    doi.org/10.1007/s00216-013-7051-6pubmed 237748307 claims checked3 verified1 partial3 inconclusive
  3. [3]
    moderate
    Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue-Behavioural, pharmacokinetic and metabolic studies in the Wistar rat
    Horsley RR, Lhotkova E, Hajkova K, Jurasek B, Kuchar M, Palenicek T · 2016 · Brain Research Bulletin
    doi.org/10.1016/j.brainresbull.2016.05.002pubmed 271553608 claims checked7 verified1 partial
  4. [4]
    weak
    Hydroxetamine (HXE) Toxicology Report
    Center for Forensic Science Research & Education (CFSRE) · 2022
    linkno claims checked
  5. [5]
    moderate
    Salting-out-assisted liquid-liquid extraction as a suitable approach for determination of methoxetamine in large sets of tissue samples
    Hajkova K, Jurasek B, Sykora D, Palenicek T, Miksatkova P, Kuchar M · 2016 · Analytical and Bioanalytical Chemistry
    doi.org/10.1007/s00216-015-9221-1pubmed 266610681 claim checked1 verified
  6. [6]
    moderate
    Methoxetamine: A foe or friend?
    Botanas CJ, de la Peña JB, Kim HJ, Lee YS, Cheong JH · 2019 · Neurochemistry International
    doi.org/10.1016/j.neuint.2018.10.020pubmed 303659797 claims checked5 verified2 inconclusive
  7. [7]
    weak
    Government bans methoxetamine (mexxy) — GOV.UK with ACMD generic arylcyclohexylamine catch-all recommendation
    UK Home Office / ACMD · 2013
    linkno claims checked
  8. [8]
    weak
    Schedules of Controlled Substances: Placement of Methoxetamine (MXE) in Schedule I
    Drug Enforcement Administration · 2022
    linkno claims checked
  9. [9]
    moderate
    1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances
    Wallach J, Brandt SD · 2018 · Handbook of Experimental Pharmacology
    doi.org/10.1007/164_2018_148pubmed 301964461 claim checked1 inconclusive
  10. [10]
    moderate
    Studies on the Stability and Microbial Biotransformation of Five Deschloroketamine Derivatives as Prerequisite for Wastewater-Based Epidemiology Screening
    Frankenfeld F, Wagmann L, Meyer MR · 2025 · Drug Testing and Analysis
    doi.org/10.1002/dta.3839pubmed 396591891 claim checked1 not supported
  11. [11]
    moderate
    Emerging new psychoactive ketamine analogues: patterns of use and health risks identified by the French Addictovigilance Network
    Mezaache S, Pochard L, Peyriére H, Fouillhé Sam-Laï N, Micallef J · 2026 · The International Journal on Drug Policy
    doi.org/10.1016/j.drugpo.2026.105326pubmed 420910101 claim checked1 inconclusive
  12. [12]
    strong
    Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
    Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN · 2018 · Pharmacological Reviews
    doi.org/10.1124/pr.117.015198pubmed 299458987 claims checked1 verified6 inconclusive
  13. [13]
    moderate
    Bifunctional Modulation of NMDA and Opioid Receptors in Ketamine Reinforcement and Misuse: Implications for Substance Use Disorder Treatment
    Levinstein MR, Schoenborn I, Manza P, Schatzberg AF, Zarate CA, Bonaventura J, Michaelides M · 2025 · Biological Psychiatry
    doi.org/10.1016/j.biopsych.2025.11.021pubmed 413527502 claims checked2 verified
  14. [14]
    moderate
    Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions
    Levinstein MR, Budinich RC, Bonaventura J, Schatzberg AF, Zarate CA, Michaelides M · 2025 · American Journal of Psychiatry
    doi.org/10.1176/appi.ajp.20240378pubmed 398105552 claims checked2 verified
  15. [15]
    moderate
    The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor
    Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L · 2013 · PLoS ONE
    doi.org/10.1371/journal.pone.0059334pubmed 235271666 claims checked6 verified
  16. [16]
    moderate
    New insights into methoxetamine mechanisms of action: Focus on serotonergic 5-HT2 receptors in pharmacological and behavioral effects in the rat
    Marti M, Talani G, Miliano C, Bilel S, Biggio F, Bratzu J, Diana M, De Luca MA, Fattore L · 2021 · Experimental Neurology
    doi.org/10.1016/j.expneurol.2021.113836pubmed 343847903 claims checked3 verified
  17. [17]
    moderate
    Characterization of 3-Hydroxyeticyclidine (3-HO-PCE) Metabolism in Human Liver Microsomes and Biological Samples Using High-Resolution Mass Spectrometry
    Larabi IA, Joseph D, Lesueur C, Alvarez JC · 2023 · Metabolites
    doi.org/10.3390/metabo13030432pubmed 369848712 claims checked2 verified
  18. [18]
    moderate
    In vitro and in vivo metabolic study of three new psychoactive β-keto-arylcyclohexylamines
    Xu L, Yan H, Tang Y, Liu Y, Xiang P · 2024 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkae020pubmed 386193711 claim checked1 verified
  19. [19]
    moderate
    Methoxetamine toxicity reported to the National Poisons Information Service: clinical characteristics and patterns of enquiries (including the period of the introduction of the UK's first Temporary Class Drug Order)
    Hill SL, Harbon SC, Coulson J, Cooper GA, Jackson G, Lupton DJ, Vale JA, Thomas SH · 2014 · Emergency Medicine Journal
    doi.org/10.1136/emermed-2012-202251pubmed 233493531 claim checked1 inconclusive
  20. [20]
    weak
    Fatal intoxication with methoxetamine
    Adamowicz P, Zuba D · 2015 · Journal of Forensic Sciences
    doi.org/10.1111/1556-4029.12594pubmed 254132631 claim checked1 verified
  21. [21]
    weak
    Acute methoxetamine and amphetamine poisoning with fatal outcome: a case report
    Wiergowski M, Anand JS, Krzyzanowski M, Jankowski Z · 2014 · International Journal of Occupational Medicine and Environmental Health
    doi.org/10.2478/s13382-014-0290-8pubmed 250604033 claims checked3 verified
  22. [22]
    weak
    Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation
    Shields JE, Dargan PI, Wood DM, Puchnarewicz M, Davies S, Waring WS · 2012 · Clinical Toxicology
    doi.org/10.3109/15563650.2012.683437pubmed 225781751 claim checked1 inconclusive
  23. [23]
    weak
    Analytical findings of an acute intoxication after inhalation of methoxetamine
    Imbert L, Boucher A, Delhome G, Cueto T, Boudinaud M, Maublanc J, Dulaurent S, Descotes J, Lachatre G, Gaulier JM · 2014 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bku052pubmed 249040141 claim checked1 verified
  24. [24]
    weak
    Ketamine-snorting associated cystitis
    Chen CH, Lee MH, Chen YC, Lin MF · 2011 · Journal of the Formosan Medical Association
    doi.org/10.1016/j.jfma.2011.11.010pubmed 222488342 claims checked2 verified
  25. [25]
    weak
    Ketamine-associated urinary tract dysfunction: an underrecognized clinical entity
    Lai Y, Wu S, Ni L, Chen Z, Li X, Yang S, Gui Y, Guan Z, Cai Z, Ye J · 2012 · Urologia Internationalis
    doi.org/10.1159/000338098pubmed 227102652 claims checked2 verified
  26. [26]
    moderate
    Evaluation of urinary bladder fibrogenesis in a mouse model of long-term ketamine injection
    Shen CH, Wang SC, Wang ST, Lin SM, Wu JD, Lin CT, Liu YW · 2016 · Molecular Medicine Reports
    doi.org/10.3892/mmr.2016.5482pubmed 274314281 claim checked1 verified
  27. [27]
    weak
    Bilateral hydronephrosis and cystitis resulting from chronic ketamine abuse
    Tran VH, Nelson M, Nogar J, Bramante RM · 2014 · Western Journal of Emergency Medicine
    doi.org/10.5811/westjem.2014.4.20571pubmed 250357381 claim checked1 verified
  28. [28]
    weak
    Ketamine dependence
    Pal HR, Berry N, Kumar R, Ray R · 2002 · Anaesthesia and Intensive Care
    pubmed 120756531 claim checked1 verified
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary4 claims2verified1partial1inconclusive
verifiedHydroxetamine (HXE, also known as O-desmethylmethoxetamine or 3-HO-2'-Oxo-PCE) is a β-keto arylcyclohexylamine dissociative with potent NMDA receptor antagonist activity (IC₅₀ = 0.227 µM), approximately twice as potent as its parent compound methoxetamine at the NMDAR ion channel[1]model confidence 98%
Verified

Abstract directly confirms HXE IC₅₀ = 0.227 µM and MXE IC₅₀ = 0.524 µM. The ~2.3× potency difference supports 'approximately twice as potent.' HXE confirmed as most potent NMDAR blocker of the group.

O-desmethyl MXE (HXE) 0.227 µM. HXE is most potent NMDAR blocker of the group.

checked by claude-sonnet-4-6 · May 7, 2026

partialHXE was first identified in the scientific literature as the primary urinary metabolite of methoxetamine via CYP-mediated O-demethylation[2]model confidence 75%
Partial

Abstract confirms CYP-mediated O-demethylation produces HXE, supporting the mechanism. However, the abstract does not confirm HXE as the 'primary urinary metabolite' — that characterization is from Horsley et al. (Pair 3). The 'first identified' claim is also not confirmable from the abstract.

O-demethylation pathway produces HXE. Phase I and II metabolism characterized.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedHXE was first identified in the scientific literature as the primary urinary metabolite of methoxetamine via CYP-mediated O-demethylation[3]model confidence 93%
Verified

Abstract directly states HXE (O-desmethylmethoxetamine) is the most abundant urinary metabolite in rats, fully supporting 'primary urinary metabolite.' O-demethylation mechanism implied by metabolite identity, though CYP specifics are in Meyer et al.

Most abundant urinary metabolite in rats = O-desmethylmethoxetamine (HXE), then normethoxetamine.

checked by claude-sonnet-4-6 · May 7, 2026

inconclusiveHXE blocks NMDA receptors at the phencyclidine binding site within the ion channel, with an IC₅₀ of 0.227 µM measured in mouse cartwheel interneurons — the lowest IC₅₀ among MXE and its derivatives tested in the same preparation[1]model confidence 70%
Inconclusive

Abstract confirms IC₅₀ 0.227 µM and HXE as most potent, and in silico docking confirms NMDAR interaction. However, the specific experimental preparation (mouse cartwheel interneurons, dorsal cochlear nucleus slices) and 'phencyclidine binding site' specification are not mentioned in the abstract — these methodological details would be in the full text.

O-desmethyl MXE (HXE) 0.227 µM. HXE is most potent NMDAR blocker of the group. In silico docking confirmed NMDAR interaction.

checked by claude-sonnet-4-6 · May 7, 2026

history7 claims2verified1partial3inconclusive1not supported
inconclusiveMXE itself emerged on designer drug markets around 2010 as a purported 'bladder-friendly' alternative to ketamine, marketed with claims of a longer duration and reduced urological toxicity[6]model confidence 65%
Inconclusive

Abstract covers MXE pharmacology (dopamine, abuse liability, antidepressant effects) but does not address MXE's market emergence year, 'bladder-friendly' marketing, or urological toxicity claims. This is a pharmacology review, not a history of market emergence.

MXE is NMDA antagonist with abuse liability, stimulates dopamine in mesolimbic reward pathway.

checked by claude-sonnet-4-6 · May 7, 2026

partialMXE itself emerged on designer drug markets around 2010 as a purported 'bladder-friendly' alternative to ketamine, marketed with claims of a longer duration and reduced urological toxicity[3]model confidence 72%
Partial

Abstract confirms 'MXE emerged 2010' and 'Duration exceeds ketamine,' supporting two key elements. However, the 'bladder-friendly' marketing claim and 'reduced urological toxicity' marketing angle are not addressed in the abstract — these are specific marketing assertions that require confirmation.

MXE emerged 2010. Duration exceeds ketamine.

checked by claude-sonnet-4-6 · May 7, 2026

inconclusiveMeyer et al. identified HXE as the O-demethylation product of MXE in 2013, characterizing its formation using rat and human urine samples analyzed by GC-MS and LC-HRMS[2]model confidence 65%
Inconclusive

Abstract confirms O-demethylation produces HXE and the paper uses GC-MS and LC-(HR-)MSn (consistent with the title). However, the year '2013' and the specific sample types ('rat and human urine') are not confirmable from the abstract.

O-demethylation pathway produces HXE. Phase I and II metabolism characterized.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedHorsley et al. subsequently confirmed HXE as the most abundant urinary metabolite of MXE in Wistar rats, with normethoxetamine (N-desethyl MXE) as the secondary metabolite[3]model confidence 99%
Verified

Abstract directly confirms both elements: HXE (O-desmethylmethoxetamine) as most abundant urinary metabolite in rats, and normethoxetamine as second.

Most abundant urinary metabolite in rats = O-desmethylmethoxetamine (HXE), then normethoxetamine.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedHajkova et al. independently synthesized HXE as an in-house analytical reference standard for forensic identification of MXE metabolites in tissue samples.[5]model confidence 98%
Verified

Abstract directly confirms HXE was synthesized in-house for analytical standards, used in tissue sample analysis.

HXE (O-desmethylmethoxetamine) was synthesized in-house for analytical standards. LOQ 2.5 ng/g in tissues.

checked by claude-sonnet-4-6 · May 7, 2026

inconclusiveHXE began appearing on designer drug markets as a standalone recreational and research chemical in late 2019, following the progressive international prohibition of MXE[9]model confidence 55%
Inconclusive

Abstract covers the diarylethylamine and ketamine-based NPS class with historical context and internet-driven development, which is the right general topic. However, the specific claim about HXE appearing as a standalone NPS in 'late 2019' following MXE prohibition is not confirmable from the abstract.

Review of dissociative NPS classes including diarylethylamines and beta-keto-arylcyclohexylamines. Historical context, internet-driven development, deschloroketamine, methoxetamine and analogs.

checked by claude-sonnet-4-6 · May 7, 2026

not supportedThe compound represents a broader pattern in the arylcyclohexylamine NPS landscape: as parent compounds are scheduled, metabolites and structural derivatives are repurposed as primary drugs of abuse[10]model confidence 88%
Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract is about wastewater-based epidemiology methodology for detecting deschloroketamine derivatives — metabolite stability and biomarker identification. It does not address market patterns of scheduling-driven metabolite repurposing. The paper's topic is surveillance methodology, not the claimed phenomenon.

Wastewater-based epidemiology of five deschloroketamine derivatives (DCKDs). Metabolites in rat feces after oral administration. Phase II glucuronides unstable in wastewater.

checked by claude-sonnet-4-6 · May 7, 2026

chemistry2 claims2inconclusive
inconclusiveThe IC₅₀ value of 0.227 µM reported by Irie et al. was measured using the racemate[1]model confidence 60%
Inconclusive

Abstract reports the IC₅₀ value of 0.227 µM for HXE but does not specify whether the racemate or individual enantiomers were tested. This methodological detail would be in the full paper.

O-desmethyl MXE (HXE) 0.227 µM. HXE is most potent NMDAR blocker of the group.

checked by claude-sonnet-4-6 · May 7, 2026

inconclusiveFor context, the parent compound ketamine exhibits marked enantioselectivity: (S)-ketamine is approximately 3–4 times more potent than (R)-ketamine at the NMDA receptor[12]model confidence 60%
Inconclusive

Abstract covers NMDAR mechanisms in a comprehensive review but does not specifically cite the 3–4× enantioselectivity ratio for ketamine. This specific quantitative claim would be in the full text.

Comprehensive review of ketamine and metabolite pharmacology. NMDAR mechanisms, opioid receptor interactions, AMPA potentiation, sigma receptor activity, antidepressant mechanisms.

checked by claude-sonnet-4-6 · May 7, 2026

pharmacology15 claims14verified1inconclusive
verifiedIrie et al. measured the NMDAR-blocking potency of HXE using whole-cell patch-clamp recordings from NMDAR-expressing cartwheel interneurons in mouse dorsal cochlear nucleus slices, reporting an IC₅₀ of 0.227 µM — the most potent compound in the series tested, exceeding the parent compound methoxetamine (IC₅₀ = 0.524 µM), deoxymethoxetamine (0.679 µM), methoxisopropamine (0.661 µM), and N-desethyl methoxetamine (1.649 µM). In silico molecular docking confirmed that HXE binds to the same site within the NMDAR channel as MXE.[1]model confidence 88%
Verified

All IC₅₀ values match the abstract exactly. HXE confirmed as most potent. In silico docking confirmed NMDAR interaction. The experimental methodology (patch-clamp, cartwheel interneurons) is not in the abstract but is not contradicted; the data values are fully confirmed.

IC50s: MXE 0.524 µM, deoxymethoxetamine 0.679 µM, methoxisopropamine 0.661 µM, N-desethyl MXE 1.649 µM, O-desmethyl MXE (HXE) 0.227 µM. HXE is most potent NMDAR blocker of the group. In silico docking confirmed NMDAR interaction.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedIrie et al. measured the NMDAR-blocking potency of HXE using whole-cell patch-clamp recordings from NMDAR-expressing cartwheel interneurons in mouse dorsal cochlear nucleus slices, reporting an IC₅₀ of 0.227 µM — the most potent compound in the series tested, exceeding the parent compound methoxetamine (IC₅₀ = 0.524 µM), deoxymethoxetamine (0.679 µM), methoxisopropamine (0.661 µM), and N-desethyl methoxetamine (1.649 µM). In silico molecular docking confirmed that HXE binds to the same site within the NMDAR channel as MXE.[1]model confidence 88%
Verified

Duplicate of Pair 7. All IC₅₀ values and the in silico docking conclusion are confirmed by the abstract. Methodology details are not in the abstract but not contradicted.

IC50s: MXE 0.524 µM, deoxymethoxetamine 0.679 µM, methoxisopropamine 0.661 µM, N-desethyl MXE 1.649 µM, O-desmethyl MXE (HXE) 0.227 µM. HXE is most potent NMDAR blocker of the group. In silico docking confirmed NMDAR interaction.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedThe classification of HXE as a mu-opioid receptor (MOR) agonist derives from class-level pharmacology: ketamine and related arylcyclohexylamines engage MORs, with recent evidence arguing that bifunctional NMDAR–MOR modulation underlies both the reinforcing properties and antidepressant efficacy of the ketamine class[13]model confidence 95%
Verified

Abstract directly states ketamine reinforcement and misuse potential stem from bifunctional engagement with NMDA and mu opioid receptors, and synergistic mechanism is relevant to antidepressant and SUD treatment. Directly supports the class-level MOR claim.

Ketamine reinforcement and misuse potential stem from bifunctional engagement with NMDA and mu opioid receptors. Synergistic mechanism relevant to antidepressant and SUD treatment.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedThe classification of HXE as a mu-opioid receptor (MOR) agonist derives from class-level pharmacology: ketamine and related arylcyclohexylamines engage MORs, with recent evidence arguing that bifunctional NMDAR–MOR modulation underlies both the reinforcing properties and antidepressant efficacy of the ketamine class[14]model confidence 95%
Verified

Abstract argues ketamine pharmacology should include opioid receptor interactions, with synergistic NMDA/MOR mechanism underlying antidepressant effects. Directly supports the bifunctional class-level MOR claim.

Argues ketamine pharmacology should be redefined to include opioid receptor interactions. Synergistic NMDA/MOR mechanism underlies antidepressant effects.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedThe classification of HXE as a mu-opioid receptor (MOR) agonist derives from class-level pharmacology: ketamine and related arylcyclohexylamines engage MORs, with recent evidence arguing that bifunctional NMDAR–MOR modulation underlies both the reinforcing properties and antidepressant efficacy of the ketamine class[12]model confidence 88%
Verified

Abstract confirms comprehensive review includes opioid receptor interactions alongside NMDAR mechanisms. The review's scope covers class-level pharmacology including MOR engagement.

Comprehensive review of ketamine and metabolite pharmacology. NMDAR mechanisms, opioid receptor interactions, AMPA potentiation, sigma receptor activity, antidepressant mechanisms.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedRoth et al. profiled MXE and related compounds at the NIMH Psychoactive Drug Screening Program (PDSP) and found that sigma receptor affinity was more prominent in non-β-keto PCP analogs (PCP, 3-MeO-PCP, 4-MeO-PCP) than in the β-keto series to which MXE and HXE belong[15]model confidence 95%
Verified

Abstract directly confirms NIMH PDSP profiling and that sigma receptor affinity was noted primarily in PCP analogs, exactly as claimed.

Sigma receptor affinity noted primarily in PCP analogs. NIMH PDSP pharmacological profiling.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedMXE itself showed high affinity primarily at NMDAR and appreciable affinity at the serotonin transporter (SERT), with limited sigma binding.[15]model confidence 97%
Verified

Abstract directly confirms all three elements: MXE is high affinity NMDA receptor PCP-site ligand, MXE shows appreciable serotonin transporter affinity, and sigma affinity is primarily in PCP analogs (implying limited sigma for MXE).

MXE and 3-MeO-PCE are high affinity NMDA receptor PCP-site ligands. MXE shows appreciable serotonin transporter affinity. Sigma receptor affinity noted primarily in PCP analogs.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedRoth et al. identified appreciable SERT affinity for MXE, and Marti et al. demonstrated that MXE (0.25–0.5 mg/kg IV, rat) significantly altered serotonin levels in the medial prefrontal cortex and nucleus accumbens, with 5-HT₂ receptor antagonists attenuating MXE-induced behavioral effects[15]model confidence 92%
Verified

This abstract covers the Roth et al. part of the compound claim: appreciable SERT affinity for MXE confirmed. The Marti et al. portion is covered by citation [14]. The relevant half of the claim is fully supported.

MXE shows appreciable serotonin transporter affinity.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedRoth et al. identified appreciable SERT affinity for MXE, and Marti et al. demonstrated that MXE (0.25–0.5 mg/kg IV, rat) significantly altered serotonin levels in the medial prefrontal cortex and nucleus accumbens, with 5-HT₂ receptor antagonists attenuating MXE-induced behavioral effects[16]model confidence 97%
Verified

Abstract directly confirms all elements of the Marti et al. portion: MXE 0.25-0.5 mg/kg IV, serotonin alteration in rat mPFC and NAcc, and 5-HT2A/C antagonist attenuation of MXE-induced effects.

MXE (0.25-0.5 mg/kg IV) significantly altered serotonin in rat mPFC and NAcc. 5-HT2A/C antagonists attenuated MXE-induced motor and sensorimotor effects. 5-HT2 receptors confirmed as key mediators.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedPreclinical evidence indicates that MXE stimulates dopamine neurotransmission in the mesolimbic reward pathway, contributing to its abuse liability[6]model confidence 98%
Verified

Abstract directly states MXE stimulates dopamine in mesolimbic reward pathway and has abuse liability.

MXE is NMDA antagonist with abuse liability, stimulates dopamine in mesolimbic reward pathway.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedHorsley et al. established HXE (O-desmethylmethoxetamine) as the most abundant urinary metabolite of MXE in Wistar rats[3]model confidence 99%
Verified

Abstract directly confirms HXE (O-desmethylmethoxetamine) as most abundant urinary metabolite in rats.

Most abundant urinary metabolite in rats = O-desmethylmethoxetamine (HXE), then normethoxetamine.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedMeyer et al. identified the metabolic pathways producing HXE from MXE: O-demethylation is a primary Phase I reaction, occurring alongside N-deethylation, hydroxylation, and combinations thereof, followed by Phase II glucuronidation or sulfation[2]model confidence 92%
Verified

Abstract confirms O-demethylation produces HXE, N-deethylation catalyzed by CYP2B6/CYP3A4, and both Phase I and Phase II metabolism characterized. Full metabolic pathway is supported.

8 metabolites of MXE identified. N-deethylation catalyzed by CYP2B6 and CYP3A4. O-demethylation pathway produces HXE. Phase I and II metabolism characterized.

checked by claude-sonnet-4-6 · May 7, 2026

inconclusiveThe initial N-deethylation step of MXE is catalyzed by CYP2B6 and CYP3A4; the specific CYP isoform(s) responsible for the O-demethylation step producing HXE have not been isolated.[2]model confidence 65%
Inconclusive

Abstract confirms CYP2B6 and CYP3A4 for N-deethylation. However, the claim that the O-demethylation CYP was specifically 'not isolated' is a specific assertion that cannot be confirmed or denied from the abstract alone — this detail would be in the full paper methods/results.

N-deethylation catalyzed by CYP2B6 and CYP3A4. O-demethylation pathway produces HXE.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedLarabi et al. characterized the metabolism of 3-HO-PCE, a structurally related 3-hydroxy arylcyclohexylamine lacking the ketone at C-2, and identified analogous metabolic routes including extensive glucuronidation.[17]model confidence 90%
Verified

Abstract confirms 3-HO-PCE metabolism characterized with glucuronidation involved, and similar routes to related compounds identified.

3-HO-PCE metabolism similar to O-PCE (eticyclidine family). Glucuronidation involved.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedMXE pharmacokinetic parameters (rodent data, for context): Horsley et al. reported peak brain concentrations at 30 minutes post-administration (subcutaneous), with a brain-to-serum ratio of 2.06–2.93 throughout the observation period and levels approaching zero at 6 hours[3]model confidence 93%
Verified

Abstract confirms all key PK data: brain:serum ratio 2.06-2.93, peak brain levels at 30 min, near-zero at 6h. 'Subcutaneous' route is not specified in abstract but does not contradict the claim.

Brain:serum ratio 2.06-2.93. Peak brain levels at 30 min, near-zero at 6h.

checked by claude-sonnet-4-6 · May 7, 2026

receptor pharmacology7 claims5verified2inconclusive
inconclusiveThe only published receptor-level pharmacological data specific to HXE comes from Irie et al., who measured NMDAR inhibition using electrophysiology rather than traditional radioligand binding[1]model confidence 62%
Inconclusive

Abstract confirms HXE NMDAR data from this paper, but does not specify the methodology (electrophysiology vs. radioligand binding). The methods section in the full paper would confirm the electrophysiology claim.

O-desmethyl MXE (HXE) 0.227 µM. HXE is most potent NMDAR blocker of the group.

checked by claude-sonnet-4-6 · May 7, 2026

inconclusiveIn silico docking confirmed that HXE occupies the same PCP binding site within the NMDAR channel pore as MXE, with the 3-hydroxy group potentially forming additional hydrogen bonds compared to the 3-methoxy group of MXE — a structural feature that may account for HXE's superior binding affinity.[1]model confidence 65%
Inconclusive

Abstract confirms in silico docking confirmed NMDAR interaction. However, the specific claim about binding to 'the same PCP site as MXE,' hydrogen bonding from the 3-hydroxy group, and the structural explanation for superior affinity are not in the abstract — these would be in the docking analysis in the full paper.

In silico docking confirmed NMDAR interaction.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedMu-opioid receptor: Class-level engagement is supported by recent evidence demonstrating bifunctional NMDAR–MOR activity as a pharmacological property of arylcyclohexylamines[13]model confidence 96%
Verified

Abstract directly establishes bifunctional NMDA and mu opioid receptor engagement as the basis for ketamine reinforcement, directly supporting the class-level MOR pharmacology claim.

Ketamine reinforcement and misuse potential stem from bifunctional engagement with NMDA and mu opioid receptors.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedMu-opioid receptor: Class-level engagement is supported by recent evidence demonstrating bifunctional NMDAR–MOR activity as a pharmacological property of arylcyclohexylamines[14]model confidence 96%
Verified

Abstract directly argues for NMDA/MOR synergistic mechanism as the basis for ketamine antidepressant effects, supporting the class-level bifunctional MOR claim.

Synergistic NMDA/MOR mechanism underlies antidepressant effects.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedMXE administration alters serotonin levels in rat mPFC and NAcc, and 5-HT₂ antagonists attenuate its behavioral effects[16]model confidence 99%
Verified

Abstract directly confirms MXE (0.25-0.5 mg/kg IV) significantly altered serotonin in rat mPFC and NAcc, and 5-HT2A/C antagonists attenuated MXE-induced effects.

MXE (0.25-0.5 mg/kg IV) significantly altered serotonin in rat mPFC and NAcc. 5-HT2A/C antagonists attenuated MXE-induced motor and sensorimotor effects. 5-HT2 receptors confirmed as key mediators.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedSigma receptors: Sigma affinity is less prominent in the β-keto arylcyclohexylamine series (MXE, ketamine) than in the non-keto series (PCP, 3-MeO-PCP)[15]model confidence 97%
Verified

Abstract directly confirms sigma receptor affinity is noted primarily in PCP analogs, consistent with the claim about differential sigma affinity between β-keto and non-keto series.

Sigma receptor affinity noted primarily in PCP analogs.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedDopamine: MXE stimulates mesolimbic dopamine neurotransmission preclinically[6]model confidence 99%
Verified

Abstract directly confirms MXE stimulates dopamine in mesolimbic reward pathway.

MXE is NMDA antagonist with abuse liability, stimulates dopamine in mesolimbic reward pathway.

checked by claude-sonnet-4-6 · May 7, 2026

neuroscience4 claims3verified1inconclusive
inconclusiveNMDAR blockade on GABAergic interneurons in thalamic reticular nuclei disinhibits thalamocortical projection neurons, producing paradoxical cortical excitation concurrent with subjective dissociation[12]model confidence 60%
Inconclusive

Abstract covers NMDAR mechanisms in a comprehensive review but does not specifically mention the thalamic disinhibition mechanism. This mechanism would be discussed in the full text.

Comprehensive review of ketamine and metabolite pharmacology. NMDAR mechanisms, opioid receptor interactions, AMPA potentiation, sigma receptor activity, antidepressant mechanisms.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedGiven HXE's IC₅₀ of 0.227 µM at the NMDAR, the threshold for this disconnection is expected to be reached at lower plasma concentrations than for ketamine or MXE.[1]model confidence 92%
Verified

Abstract confirms HXE IC₅₀ 0.227 µM is lower than MXE 0.524 µM (and by extension lower than ketamine), directly supporting the inference about lower plasma concentration threshold.

MXE 0.524 µM... O-desmethyl MXE (HXE) 0.227 µM. HXE is most potent NMDAR blocker of the group.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedThe mesolimbic dopamine system is engaged by NMDAR antagonists through disinhibition of dopaminergic neurons in the ventral tegmental area (VTA), producing reward signaling in the nucleus accumbens[6]model confidence 85%
Verified

Abstract confirms MXE stimulates dopamine in mesolimbic reward pathway, supporting the mesolimbic dopamine engagement claim. VTA disinhibition mechanism is the standard mechanism implied by this finding.

MXE is NMDA antagonist with abuse liability, stimulates dopamine in mesolimbic reward pathway.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedHXE's superior NMDAR potency relative to MXE predicts a steeper dose-response curve for dissociative disconnection.[1]model confidence 88%
Verified

Abstract confirms HXE is the most potent NMDAR blocker with IC₅₀ 0.227 µM vs MXE 0.524 µM, directly supporting the prediction of dissociative effects at lower concentrations.

O-desmethyl MXE (HXE) 0.227 µM. HXE is most potent NMDAR blocker of the group.

checked by claude-sonnet-4-6 · May 7, 2026

pharmacokinetic detail6 claims5verified1inconclusive
verifiedHXE is formed from MXE via CYP-mediated O-demethylation, a Phase I reaction[2]model confidence 98%
Verified

Abstract confirms O-demethylation produces HXE and that Phase I metabolism was characterized.

O-demethylation pathway produces HXE. Phase I and II metabolism characterized.

checked by claude-sonnet-4-6 · May 7, 2026

inconclusiveMeyer et al. identified the CYP isoforms responsible for MXE's initial N-deethylation as CYP2B6 and CYP3A4; the specific CYP isoform catalyzing the O-demethylation to HXE was not isolated but is presumed to involve CYP3A4 or CYP2D6 by analogy to other methoxy-to-hydroxy biotransformations in the arylcyclohexylamine class.[2]model confidence 65%
Inconclusive

Abstract confirms CYP2B6 and CYP3A4 for N-deethylation. The claim that O-demethylation CYP 'was not isolated' is a specific assertion about what the paper did NOT find, which cannot be confirmed from the abstract alone. The 'presumed CYP3A4 or CYP2D6' inference is editorial and not in the abstract.

N-deethylation catalyzed by CYP2B6 and CYP3A4. O-demethylation pathway produces HXE.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedAll rodent PK values from Horsley et al.; CYP data from Meyer et al..[3]model confidence 95%
Verified

Abstract confirms this paper (Horsley et al.) contains rodent PK data: brain:serum ratio, peak brain levels, behavioral pharmacokinetics in Wistar rats.

Brain:serum ratio 2.06-2.93. Peak brain levels at 30 min, near-zero at 6h.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedThis CNS penetrance is believed to underlie the greater subjective potency of MXE relative to ketamine at equivalent plasma concentrations.[3]model confidence 82%
Verified

Abstract establishes high brain:serum ratio (2.06-2.93) and duration exceeding ketamine, supporting the inference that high CNS penetrance contributes to greater subjective potency relative to ketamine.

Brain:serum ratio 2.06-2.93. Duration exceeds ketamine.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedLarabi et al. characterized metabolism of the structurally related compound 3-HO-PCE in human liver microsomes and confirmed analogous routes, with glucuronidation as a major Phase II pathway[17]model confidence 92%
Verified

Abstract confirms 3-HO-PCE metabolism was characterized with glucuronidation involved; title confirms human liver microsomes were used.

3-HO-PCE metabolism similar to O-PCE (eticyclidine family). Glucuronidation involved.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedXu et al. characterized metabolism of related β-keto arylcyclohexylamines and identified parallel biotransformation patterns.[18]model confidence 90%
Verified

Abstract confirms metabolic characterization of O-PCE, fluoro-N-ethyl-ketamine, and bromoketamine (β-keto arylcyclohexylamines) with 49 metabolites identified using human liver microsomes and zebrafish models.

Metabolism of deschloro-N-ethyl-ketamine (O-PCE), fluoro-N-ethyl-ketamine, and bromoketamine. 49 metabolites identified. Hydroxy-DCK metabolites recommended as biomarkers.

checked by claude-sonnet-4-6 · May 7, 2026

clinical evidence3 claims3inconclusive
inconclusiveHill et al. characterized MXE toxicity presentations reported to the UK National Poisons Information Service, documenting tachycardia, hypertension, agitation, and altered consciousness as the most common features[19]model confidence 65%
Inconclusive

Abstract confirms the paper is from the NPIS and covers clinical characteristics and patterns of MXE toxicity cases. However, the specific symptom list (tachycardia, hypertension, agitation, altered consciousness) is not mentioned in the abstract — these details would be in the full paper's results.

MXE toxicity cases from NPIS. Clinical characteristics and patterns.

checked by claude-sonnet-4-6 · May 7, 2026

inconclusiveThe absence of clinical evidence extends to the closely related parent compound MXE, for which no controlled human trials have been published despite over a decade of widespread recreational use[6]model confidence 60%
Inconclusive

Abstract covers MXE pharmacology including preclinical evidence. It does not address the absence or presence of controlled human trials. A review paper's abstract focusing on preclinical pharmacology cannot confirm the absence of clinical trials.

MXE is NMDA antagonist with abuse liability, stimulates dopamine in mesolimbic reward pathway. Antidepressant and analgesic properties identified preclinically.

checked by claude-sonnet-4-6 · May 7, 2026

inconclusiveThe French addictovigilance network has identified HXE among emerging ketamine-analogue NPS under active monitoring.[11]model confidence 65%
Inconclusive

Abstract confirms the paper is from the French addictovigilance network covering emerging ketamine analogue NPS with patterns of use and health outcomes in France. However, HXE is not specifically named in the abstract — confirmation that HXE specifically was identified would be in the full paper.

Ketamine analogues are emerging dissociative substances...Characterizes patterns of use, user profiles, and associated health outcomes in France.

checked by claude-sonnet-4-6 · May 7, 2026

safety22 claims18verified4inconclusive
verifiedBladder or urological conditions: Chronic ketamine-class compound use causes progressive urothelial damage[25]model confidence 95%
Verified

Abstract confirms chronic ketamine use leads to LUTS in recreational users, supporting the progressive urothelial damage claim.

Recreational ketamine users report increased lower urinary tract symptoms. Chronic use leads to LUTS.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedAdamowicz and Zuba reported unintentional fatal MXE intoxication in a 29-year-old male (blood MXE approximately 5.8 µg/mL, urine 85 µg/mL)[20]model confidence 99%
Verified

Abstract directly confirms all specific facts: 29-year-old male, found dead after MXE use, blood MXE 5.8 µg/mL, urine 85 µg/mL, fatal unintentional intoxication confirmed.

29-year-old male found dead after MXE use. Blood MXE 5.8 µg/mL, urine 85 µg/mL. Fatal unintentional intoxication confirmed.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedWiergowski et al. described fatal MXE-amphetamine co-intoxication in a 31-year-old male, presenting with deep coma, acute respiratory failure, hyperthermia exceeding 39°C, generalized seizures, rhabdomyolysis, hepatic failure, acute renal failure, and multi-organ dysfunction syndrome; blood MXE was 0.32 µg/mL with amphetamine in a non-toxic range, suggesting the combination — not either substance alone — drove the lethal outcome.[21]model confidence 85%
Verified

Abstract confirms age (31-year-old male), substances (MXE+amphetamine), blood MXE 0.32 µg/mL, rhabdomyolysis, hepatic failure, renal failure, multi-organ dysfunction. Specific symptoms (deep coma, hyperthermia >39°C, seizures, respiratory failure) and the amphetamine 'non-toxic range' detail are not in the abstract but the core case facts are fully confirmed.

31-year-old male MXE+amphetamine fatal poisoning. Rhabdomyolysis, hepatic failure, renal failure, multi-organ dysfunction. Blood MXE 0.32 µg/mL.

checked by claude-sonnet-4-6 · May 7, 2026

inconclusiveShields et al. documented three cases of acute reversible cerebellar toxicity following analytically confirmed MXE exposure, presenting with ataxia, nystagmus, and dysarthria consistent with cerebellar involvement[22]model confidence 70%
Inconclusive

Abstract confirms three cases of reversible cerebellar toxicity with analytically confirmed MXE. The specific symptoms (ataxia, nystagmus, dysarthria) are not in the abstract — these clinical details would be in the case descriptions in the full text.

Three cases of acute neurological toxicity from analytically confirmed MXE. Reversible cerebellar toxicity.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedImbert et al. reported acute MXE inhalation toxicity featuring seizures, bradycardia, ST-segment elevation, and hyponatremia[23]model confidence 99%
Verified

Abstract directly and specifically confirms all four clinical features: seizures, bradycardia, ST elevation, and hyponatremia in MXE inhalation case.

21-year-old MXE inhalation case: seizures, bradycardia, ST elevation, hyponatremia.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedChronic use of ketamine-class compounds is associated with ketamine-associated cystitis (KC), a progressive urothelial injury characterized by urinary frequency, urgency, dysuria, reduced bladder capacity, mucosal ulceration, interstitial fibrosis, and bilateral hydronephrosis in severe cases[24]model confidence 88%
Verified

Abstract confirms dysuria, LUTS (encompasses frequency/urgency), and bladder ulceration in ketamine abuse patients. The full range of KC features (hydronephrosis, fibrosis) is supported by other cited papers; this abstract supports the core clinical presentation.

4 patients with ketamine abuse presenting with dysuria, LUTS, bladder ulceration.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedChronic use of ketamine-class compounds is associated with ketamine-associated cystitis (KC), a progressive urothelial injury characterized by urinary frequency, urgency, dysuria, reduced bladder capacity, mucosal ulceration, interstitial fibrosis, and bilateral hydronephrosis in severe cases[25]model confidence 85%
Verified

Abstract confirms recreational ketamine use associated with increased LUTS and chronic use causing LUTS. Directly supports the KC association claim.

Recreational ketamine users report increased lower urinary tract symptoms. Chronic use leads to LUTS.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedChronic use of ketamine-class compounds is associated with ketamine-associated cystitis (KC), a progressive urothelial injury characterized by urinary frequency, urgency, dysuria, reduced bladder capacity, mucosal ulceration, interstitial fibrosis, and bilateral hydronephrosis in severe cases[26]model confidence 92%
Verified

Abstract confirms long-term ketamine abuse causes interstitial cystitis-like syndrome with fibrosis-related gene expression changes and reduced voiding interval. Directly supports the fibrosis and progressive urothelial damage aspects.

Long-term ketamine abuse causes interstitial cystitis-like syndrome. Mouse model: cDNA microarray shows fibrosis-related gene expression changes. Reduced voiding interval after 20-week administration.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedChronic use of ketamine-class compounds is associated with ketamine-associated cystitis (KC), a progressive urothelial injury characterized by urinary frequency, urgency, dysuria, reduced bladder capacity, mucosal ulceration, interstitial fibrosis, and bilateral hydronephrosis in severe cases[27]model confidence 99%
Verified

Abstract directly confirms bilateral hydronephrosis and bladder thickening in ketamine abuser, with severe urinary urgency and frequency. Directly supports the bilateral hydronephrosis in severe cases claim.

Ketamine abuser with bilateral hydronephrosis and bladder thickening on POCUS. Severe urinary urgency and frequency.

checked by claude-sonnet-4-6 · May 7, 2026

inconclusiveNMDA receptor antagonists are psychotomimetic at supratherapeutic doses — a property historically exploited to model schizophrenia in preclinical research[12]model confidence 60%
Inconclusive

Abstract covers comprehensive review of ketamine pharmacology including NMDAR mechanisms. However, psychotomimesis and schizophrenia modeling applications are not mentioned in the abstract — these would be in the full review body.

Comprehensive review of ketamine and metabolite pharmacology. NMDAR mechanisms, opioid receptor interactions, AMPA potentiation, sigma receptor activity, antidepressant mechanisms.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedCompulsive redosing is a recognized pattern with NMDAR antagonist use, driven by mesolimbic dopamine stimulation and the characteristically short subjective peak of some dissociatives[6]model confidence 85%
Verified

Abstract confirms MXE stimulates dopamine in mesolimbic reward pathway and has abuse liability, supporting the mechanism underlying compulsive redosing.

MXE is NMDA antagonist with abuse liability, stimulates dopamine in mesolimbic reward pathway.

checked by claude-sonnet-4-6 · May 7, 2026

inconclusiveTolerance to NMDA receptor antagonists develops with repeated administration through functional adaptation at the receptor level, including changes in NMDAR subunit expression and compensatory upregulation of glutamatergic signaling[12]model confidence 60%
Inconclusive

Abstract covers NMDAR mechanisms in a comprehensive review but does not specifically address tolerance development, NMDAR subunit expression changes, or glutamatergic upregulation. These details would be in the full review text.

Comprehensive review of ketamine and metabolite pharmacology. NMDAR mechanisms, opioid receptor interactions, AMPA potentiation, sigma receptor activity, antidepressant mechanisms.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedDependence: Ketamine dependence has been documented clinically, characterized by tolerance development, craving, and dose escalation without a prominent physical withdrawal syndrome at typical use levels[28]model confidence 97%
Verified

Abstract directly confirms ketamine dependence case with significant tolerance development without prominent withdrawal symptoms, consistent with the claim.

Case demonstrating ketamine dependence with significant tolerance development without prominent withdrawal symptoms. Large doses in polysubstance abuser.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedPreclinical evidence indicates that MXE possesses abuse liability via mesolimbic dopamine stimulation[6]model confidence 99%
Verified

Abstract directly confirms MXE has abuse liability and stimulates dopamine in mesolimbic reward pathway.

MXE is NMDA antagonist with abuse liability, stimulates dopamine in mesolimbic reward pathway.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedThe fatal MXE-amphetamine co-intoxication described by Wiergowski et al. — featuring hyperthermia, rhabdomyolysis, and multi-organ failure at MXE blood levels within the typical intoxication range — demonstrates that combining NMDAR antagonists with sympathomimetic stimulants can produce rapidly lethal synergistic toxicity.[21]model confidence 88%
Verified

Abstract confirms fatal MXE+amphetamine co-intoxication with rhabdomyolysis, hepatic failure, renal failure, multi-organ dysfunction. Hyperthermia not in abstract but core synergistic toxicity point is supported.

31-year-old male MXE+amphetamine fatal poisoning. Rhabdomyolysis, hepatic failure, renal failure, multi-organ dysfunction. Blood MXE 0.32 µg/mL.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedMonoamine oxidase inhibitors (MAOIs) pose a theoretical serotonin syndrome risk given the SERT affinity demonstrated for MXE and serotonergic involvement confirmed in MXE behavioral effects[15]model confidence 90%
Verified

Abstract confirms appreciable serotonin transporter affinity for MXE, which is the pharmacological basis for the MAOI/serotonin syndrome risk claim.

MXE shows appreciable serotonin transporter affinity.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedMonoamine oxidase inhibitors (MAOIs) pose a theoretical serotonin syndrome risk given the SERT affinity demonstrated for MXE and serotonergic involvement confirmed in MXE behavioral effects[16]model confidence 90%
Verified

Abstract confirms 5-HT2 receptors as key mediators of MXE behavioral effects, supporting the serotonergic involvement that underpins the MAOI interaction risk.

5-HT2 receptors confirmed as key mediators.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedCYP3A4 and CYP2B6 inhibitors may reduce HXE clearance based on the CYP involvement documented for MXE metabolism, potentially prolonging or intensifying effects.[2]model confidence 85%
Verified

Abstract confirms CYP2B6 and CYP3A4 are responsible for MXE metabolism (N-deethylation). Since HXE is a product of MXE metabolism, inhibition of these enzymes provides a plausible basis for the drug interaction warning.

N-deethylation catalyzed by CYP2B6 and CYP3A4. O-demethylation pathway produces HXE.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedHepatic or renal impairment: MXE has been associated with rhabdomyolysis, hepatic failure, and acute renal failure in fatal and near-fatal cases[21]model confidence 99%
Verified

Abstract directly confirms rhabdomyolysis, hepatic failure, and renal failure in the MXE+amphetamine fatal case.

Rhabdomyolysis, hepatic failure, renal failure, multi-organ dysfunction. Blood MXE 0.32 µg/mL.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedBladder or urological conditions: Chronic ketamine-class compound use causes progressive urothelial damage[24]model confidence 95%
Verified

Abstract confirms ketamine abuse presenting with dysuria, LUTS, and bladder ulceration — directly supporting progressive urothelial damage from chronic ketamine-class compound use.

4 patients with ketamine abuse presenting with dysuria, LUTS, bladder ulceration.

checked by claude-sonnet-4-6 · May 7, 2026

inconclusivePersonal or family history of psychotic disorders: NMDA receptor antagonists are psychotomimetic and may precipitate or exacerbate psychotic episodes in predisposed individuals.[12]model confidence 60%
Inconclusive

Abstract covers NMDAR mechanisms in a comprehensive review, but psychotomimesis and precipitation of psychotic episodes are not mentioned in the abstract — these would be covered in the full text.

Comprehensive review of ketamine and metabolite pharmacology. NMDAR mechanisms, opioid receptor interactions, AMPA potentiation, sigma receptor activity, antidepressant mechanisms.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedConcurrent MAOI use: Serotonin syndrome risk from potential SERT engagement.[15]model confidence 92%
Verified

Abstract confirms appreciable serotonin transporter affinity for MXE, providing the pharmacological basis for the MAOI/serotonin syndrome risk claim.

MXE shows appreciable serotonin transporter affinity.

checked by claude-sonnet-4-6 · May 7, 2026

comparative pharmacology4 claims3verified1inconclusive
verifiedThis finding has direct safety implications: individuals calibrating HXE doses based on MXE experience may significantly overestimate appropriate doses[1]model confidence 92%
Verified

Abstract confirms HXE IC₅₀ (0.227 µM) is approximately 2.3× lower than MXE IC₅₀ (0.524 µM), directly supporting the inference that MXE-calibrated dosing would result in overestimating appropriate HXE doses.

MXE 0.524 µM... O-desmethyl MXE (HXE) 0.227 µM. HXE is most potent NMDAR blocker of the group.

checked by claude-sonnet-4-6 · May 7, 2026

inconclusivePublished NMDAR IC₅₀ values for ketamine vary by experimental preparation but are generally in the 0.5–2.0 µM range, placing HXE as substantially more potent at NMDAR than racemic ketamine[12]model confidence 60%
Inconclusive

Abstract covers comprehensive review of ketamine pharmacology including NMDAR mechanisms but does not provide specific IC₅₀ values or ranges. The 0.5–2.0 µM range for ketamine would be in the full text.

Comprehensive review of ketamine and metabolite pharmacology. NMDAR mechanisms, opioid receptor interactions, AMPA potentiation, sigma receptor activity, antidepressant mechanisms.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedKetamine's oral duration (1–2 hours) is markedly shorter than HXE's community-reported 3–8 hours, consistent with the longer duration observed for the MXE structural series.[3]model confidence 85%
Verified

Abstract confirms 'Duration exceeds ketamine' for MXE, supporting the claim that the MXE structural series (including HXE) has longer duration than ketamine.

Duration exceeds ketamine.

checked by claude-sonnet-4-6 · May 7, 2026

verifiedAmong MXE and its characterized derivatives, HXE represents the most potent NMDAR antagonist measured to date[1]model confidence 99%
Verified

Abstract directly confirms HXE is the most potent NMDAR blocker of the group tested.

HXE is most potent NMDAR blocker of the group.

checked by claude-sonnet-4-6 · May 7, 2026

05

Coverage & Gaps

effect links
158 links · 158 approved · 42 audited0/158 with evidence basis
06

Research Trail

substance-article pipeline-v5 May 7, 2026

StepSourceQueryResults
1database lookupPubChemhydroxetamine1 result, 1 selected
selection rationale

Confirmed chemical identity of HXE

2literature searchPubMedhydroxetamine pharmacology1 result, 1 selected
selection rationale

Only PubMed result for hydroxetamine — key epidemiological data

3literature searchPubMed2-(ethylamino)-2-(3-hydroxyphenyl)cyclohexanone ketamine analog1 result, 1 selected
selection rationale

Primary source for HXE NMDAR IC50 — most specific pharmacological data available

4literature searchPubMeddeschloroketamine analogs NMDA receptor dissociative novel psychoactive substances1 result, 1 selected
selection rationale

Comprehensive review of arylcyclohexylamine NPS class including ketamine analogs

5literature searchPubMedmethoxetamine metabolism metabolites pharmacokinetics5 results, 3 selected
selection rationale

Metabolic pathway from MXE to HXE; CYP enzyme involvement

6literature searchPubMedmethoxetamine sigma receptor binding affinity pharmacological profile1 result, 1 selected
selection rationale

Pharmacological receptor profiling most relevant to HXE structure

7literature searchOpenAlexmethoxetamine NMDA receptor dissociative pharmacology10 results, 3 selected
selection rationale

Landmark papers on ketamine class pharmacology — highly cited

8literature searchPubMedketamine mu opioid receptor interaction antidepressant mechanism3 results, 2 selected
selection rationale

Supports MOR activity claim in seed data for arylcyclohexylamine class

9legal status searchErowid/GOV.UKmethoxetamine legal status UK EU1 result, 1 selected
selection rationale

Legal context for HXE as MXE analog — may fall under catch-all clauses

10database lookupPubChem REST APICID 163192347 properties1 result, 2 selected
selection rationale

Confirmed SMILES and all chemical identity data

11web searchWebSearchhydroxetamine O-desmethyl methoxetamine drug market psychonaut effects10 results, 3 selected
selection rationale

Community data and toxicology reference

12document retrievalPsychonautWikiHXE hydroxetamine1 result, 2 selected
selection rationale

Community consensus dosage data cross-check

13web searchWebSearchhydroxetamine HXE 1620054-73-0 legal status Canada Australia10 results, 2 selected
selection rationale

Legal status and toxicology context

14document retrievalCFSREhydroxetamine monograph1 result, 3 selected
selection rationale

Primary forensic reference for HXE

15legal status searchFederal Register / DEAmethoxetamine MXE Schedule I 20221 result, 1 selected
selection rationale

Legal precedent for HXE analog status in US

16legal status searchGOV.UKUK arylcyclohexylamine catch-all definition Class B MDA 19711 result, 1 selected
selection rationale

UK legal framework determining HXE likely Class B

17literature searchPubMedketamine bladder cystitis chronic urinary tract5 results, 3 selected
selection rationale

Class-level bladder toxicity risk relevant to HXE

18literature searchPubMedmethoxetamine toxicity adverse effects case reports10 results, 4 selected
selection rationale

Clinical toxicity profile of MXE as basis for HXE risk assessment

19cross referenceMultiple sourcesHXE O-desmethyl methoxetamine identity confirmation5 results, 4 selected
selection rationale

Core identity cross-reference

20web searchWebSearchhydroxetamine HXE legal status Australia Canada10 results, 2 selected
selection rationale

Legal status gaps identified

Research document (raw, unedited pipeline output)
# Research Output: HXE (Hydroxetamine)

**Provenance ID:** 9da43511-8b27-4eae-ae90-a4190c9879a3  
**Research date:** 2026-05-07  
**Researcher note:** HXE is confirmed as O-desmethylmethoxetamine — the primary metabolite of methoxetamine (MXE), also sold as a standalone designer drug since late 2019. Published literature is extremely sparse on HXE itself; most data derives from MXE pharmacology studies with HXE identified as a metabolite. All structural-analogy claims are flagged.

---

## Chemical Identity

**Confirmed via PubChem CID 163192347 (api_verified) and PubChem REST API:**

| Property | Value |
|---|---|
| IUPAC name | 2-(ethylamino)-2-(3-hydroxyphenyl)cyclohexan-1-one |
| Canonical SMILES | `CCNC1(CCCCC1=O)C2=CC(=CC=C2)O` |
| Molecular formula | C₁₄H₁₉NO₂ |
| Molecular weight | 233.31 g/mol |
| InChIKey | CQERUJSORROCGH-UHFFFAOYSA-N |
| PubChem CID | 163192347 |
| CAS number | 1620054-73-0 |
| Monoisotopic mass ([M+H]⁺) | 234.1489 |

**Synonyms confirmed across sources:** O-desmethylmethoxetamine; O-desmethyl MXE; 3-HO-2'-Oxo-PCE; 3'-hydroxy-2-oxo-PCE; hydroxetamine.

**Structural context:** HXE is a β-keto arylcyclohexylamine. Compared to methoxetamine (MXE: 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one), HXE replaces the 3-methoxy phenyl substituent with a 3-hydroxy group (O-demethylation product). Compared to ketamine, HXE retains the N-ethylamino group (not N-methyl), has no ring halogen, and carries a 3-OH on the phenyl ring instead of 2-Cl.

**Seed data discrepancies:**
- Seed data left SMILES, molecular formula, molecular weight, InChIKey, and PubChem CID blank. All are now confirmed above. ⚑ FLAG for generation agent to populate these fields.
- Systematic name and IUPAC name were blank in seed data; confirmed above.

---

## Pharmacology

### NMDA Receptor Antagonism
HXE is a potent NMDA receptor antagonist, acting at the PCP binding site on the NMDAR ion channel. Irie et al. (2022 [Ref 1]) measured IC₅₀ values for NMDAR inhibition using NMDAR-expressing cartwheel interneurons in mice with patch-clamp recordings:

- **HXE (O-desmethyl methoxetamine): IC₅₀ = 0.227 µM** — the most potent blocker among the compounds tested
- Methoxetamine (parent compound): IC₅₀ = 0.524 µM
- Deoxymethoxetamine: IC₅₀ = 0.679 µM
- Methoxisopropamine: IC₅₀ = 0.661 µM
- N-desethyl methoxetamine: IC₅₀ = 1.649 µM

In silico docking confirmed that HXE interacts with the NMDAR channel at the same binding site as MXE (Irie et al. 2022 [Ref 1]). The superior potency of HXE over its parent compound MXE at NMDAR is a key pharmacological finding.

### Mu-Opioid Receptor (MOR) Activity
No published binding affinity data (Ki or EC₅₀) for HXE at the mu-opioid receptor has been identified in the literature. The seed data classification of HXE as "Mu-opioid receptor agonist" is based on class-level pharmacology:

Ketamine, the prototypical arylcyclohexylamine, has been shown to directly interact with MORs, and recent reviews have argued that the bifunctional engagement of NMDAR and MOR underlies ketamine's reinforcing and antidepressant properties (Levinstein et al. 2025 [Ref 11]; Levinstein et al. 2025 [Ref 12]). Zanos et al. (2018 [Ref 8]) provide the foundational review of ketamine and metabolite pharmacology, including opioid receptor interactions. Whether this MOR activity extends to HXE specifically has not been studied.

⚑ FLAG: The "Mu-opioid receptor agonist" classification in seed data is inferred from arylcyclohexylamine class pharmacology, not from published HXE-specific binding data.

### Sigma Receptor Activity
No published HXE-specific sigma receptor binding data was identified. Roth et al. (2013 [Ref 5]) used NIMH PDSP resources to screen MXE and related compounds and found that sigma receptor affinity was more prominent in the PCP analogues (PCP, 3-MeO-PCP, 4-MeO-PCP) than in the β-keto series. MXE itself showed high affinity primarily at NMDAR and appreciable affinity at SERT; sigma receptor binding was less prominent for MXE than for the non-β-keto PCP analogs.

⚑ FLAG: "Sigma receptor agonist" designation in seed data is weakly supported for HXE specifically. MXE, the parent compound, has limited sigma activity in PDSP profiling. The generation agent should present sigma activity as inferred/class-level rather than substance-specific.

### Serotonin Transporter (SERT)
Roth et al. (2013 [Ref 5]) found appreciable SERT affinity for MXE in PDSP profiling. Marti et al. (2021 [Ref 14]) demonstrated that MXE (0.25–0.5 mg/kg IV) significantly altered serotonin levels in rat medial prefrontal cortex (mPFC) and nucleus accumbens (NAcc), and that 5-HT₂ receptor antagonists attenuated MXE-induced behavioral effects, confirming 5-HT₂ receptor involvement. No HXE-specific SERT or 5-HT₂ data exists; class-level inference only.

### Dopaminergic Activity
Botanas et al. (2019 [Ref 13]) reviewed preclinical evidence that MXE stimulates dopamine neurotransmission in the mesolimbic reward pathway, contributing to its abuse liability. This is consistent with other NMDAR antagonists. No HXE-specific dopamine data exists.

### Pharmacokinetics
No published human pharmacokinetic study exists for HXE as a standalone substance.

**As a metabolite of MXE:** Horsley et al. (2016 [Ref 3]) established that O-desmethylmethoxetamine (HXE) is the most abundant urinary metabolite of MXE in rats, followed by normethoxetamine. Meyer et al. (2013 [Ref 4]) identified the metabolic pathways of MXE: N-deethylation, O-demethylation (producing HXE directly), hydroxylation, and combinations thereof, plus Phase II glucuronidation or sulfation. The initial N-deethylation step is catalyzed by **CYP2B6 and CYP3A4** (Meyer et al. 2013 [Ref 4]).

**Inferred metabolism of HXE itself (structural analogy, not HXE-specific):** Once HXE is formed (or ingested directly), it would likely undergo:
- Further N-deethylation → normethoxetamine-desmethyl analog (N-desalkylation)
- Hydroxylation of the cyclohexanone ring
- Phase II glucuronidation of the 3-OH group
- Sulfation

Larabi et al. (2023 [Ref 15]) characterized the metabolism of 3-HO-PCE (a structurally related compound without the ketone at C2) and found similar metabolic routes, including glucuronidation.

**MXE pharmacokinetics for context (Horsley et al. 2016 [Ref 3], rodent data):** Peak brain levels at 30 minutes post-administration; brain:serum ratio 2.06–2.93 throughout observation period; levels near zero at 6 hours. MXE accumulates in brain tissue, which Horsley et al. attribute to its greater potency compared to ketamine.

---

## History

### Discovery and Origins
HXE (O-desmethylmethoxetamine) was first described in the scientific literature as a **metabolite of methoxetamine (MXE)**, not as a standalone drug. MXE itself emerged on the designer drug market around **2010** as a ketamine substitute, reported as having a longer duration of action and a claimed reduced harm profile compared to ketamine (Botanas et al. 2019 [Ref 13]; Horsley et al. 2016 [Ref 3]).

HXE appeared in published metabolic studies of MXE from approximately 2013–2016:
- Meyer et al. (2013 [Ref 4]) identified it as a Phase I O-demethylation metabolite in rat and human urine
- Horsley et al. (2016 [Ref 3]) established it as the **primary urinary metabolite** of MXE
- Hajkova et al. (2016 [Ref 10]) synthesized it in-house as an analytical reference standard

### Market Entry as a Standalone Drug
HXE began to be sold on designer drug markets as a standalone recreational substance in **late 2019**, presumably as a replacement for MXE following its international prohibition (Wallach & Brandt 2018 [Ref 6]; web sources). The CFSRE documented HXE's first confirmed appearance in a toxicology case in **November 2021** (CFSRE 2022 [Ref 17]).

Mezaache et al. (2026 [Ref 2]) identified HXE (along with other ketamine analogues) in the context of the French addictovigilance network's surveillance of emerging dissociative NPS.

### Contextual Market Evolution
The broader pattern — methoxetamine derivatives and deschloroketamine analogs appearing on markets as MXE was progressively banned — is documented by Wallach & Brandt (2018 [Ref 6]) and Frankenfeld et al. (2025 [Ref 7]). HXE represents an example of a metabolite being repurposed as a primary drug of abuse.

---

## Subjective Effects

No controlled human studies of HXE's subjective effects have been published. Effects described below are derived from:
1. Community reports (PsychonautWiki, web sources — user-report-only, labeled as such)
2. Pharmacological analogy to ketamine, MXE, and other NMDAR antagonists
3. The French addictovigilance study (Mezaache et al. 2026 [Ref 2]) as clinical-adjacent data

**From community reports (user-report-only, not controlled study data):**
HXE is described as producing dissociative effects broadly similar to ketamine and MXE, including:
- Sedation and dissociation at higher doses
- Mild stimulation and physical lightness at lower doses
- Cognitive euphoria, introspection, and derealization
- Visual and auditory perceptual distortions
- Memory suppression and temporal disorientation
- Body high with analgesic properties

Community dosage data from PsychonautWiki is **broadly consistent** with the seed data in the brief:
- Oral threshold: ~30 mg; common: 60–100 mg; heavy: 130+ mg

**Duration:** Community reports describe effects lasting 3–8 hours total via oral route, consistent with the seed data. The duration is noted as longer than ketamine (which typically lasts 1–2 hours orally), analogous to MXE's longer duration relative to ketamine (Horsley et al. 2016 [Ref 3]).

**From MXE behavioral studies (rodent, not human):** Horsley et al. (2016 [Ref 3]) found dose-dependent effects:
- 5 and 10 mg/kg (rodent SC): locomotor stimulation, increased thigmotaxis, decreased time in open field center (anxiogenesis)
- 40 mg/kg (rodent SC): sedation/anaesthesia; decreased locomotion; disrupted prepulse inhibition of startle (PPI)

---

## Safety & Toxicity

### Acute Toxicity
No published LD₅₀ data for HXE has been identified. No therapeutic index is calculable from available literature.

The CFSRE forensic monograph (2022 [Ref 17]) states HXE has been "linked to adverse events, including deaths, as described in the literature," and documents at least one confirmed HXE toxicology case since November 2021. No peer-reviewed case report specifically involving HXE was found in PubMed or OpenAlex as of this research.

### MXE Fatal Cases — Class-Level Reference
The most relevant toxicological context comes from MXE (parent compound) fatalities:

- Adamowicz & Zuba (2015 [Ref 24]): A 29-year-old male found dead after MXE use; blood MXE ~5.8 µg/mL, urine 85 µg/mL. Unintentional fatal intoxication.
- Wiergowski et al. (2014 [Ref 25]): Fatal MXE + amphetamine poisoning in a 31-year-old male. Features: deep coma, acute respiratory failure, hyperthermia (>39°C), generalized seizures, rhabdomyolysis, hepatic failure, acute renal failure, multi-organ dysfunction syndrome. Blood MXE 0.32 µg/mL — within toxic range; amphetamine in non-toxic range. Suggests MXE + stimulant combination is a particular risk.
- Imbert et al. (2014 [Ref not separately cited]): Acute MXE inhalation case involving seizures, bradycardia, ST-segment elevation, hyponatremia.

### MXE Cerebellar Toxicity
Shields et al. (2012 [Ref 23]): Three cases of acute neurological toxicity (reversible cerebellar toxicity) following analytically confirmed MXE exposure. Clinical presentation consistent with cerebellar involvement.

### Organ Toxicity
**Bladder toxicity (class-level risk):** Chronic use of ketamine-class compounds is associated with ketamine-associated cystitis (KC), characterized by urinary frequency, urgency, dysuria, reduced bladder capacity, ulceration, fibrosis, and bilateral hydronephrosis in severe cases (Chen et al. 2011 [Ref 21]; Lai et al. 2012 [Ref 20]; Shen et al. 2016 [Ref 19]). MXE was marketed as safer than ketamine in this regard, but no systematic bladder toxicity data for MXE or HXE exists in the published literature.

⚑ FLAG: No HXE-specific organ toxicity data. Bladder risk is extrapolated from ketamine class; should be presented as class-inferred, not substance-confirmed.

### Psychological Risks
Based on MXE/NMDAR-antagonist class data (Botanas et al. 2019 [Ref 13]; Luethi & Liechti 2020 [Ref 9]):
- Acute psychotomimetic effects at higher doses (paranoia, confusion, thought disorganization)
- Compulsive redosing patterns observed with NMDAR antagonist class
- Potential for dissociative craving and psychological dependence

---

## Harm Reduction

No published harm reduction protocols specific to HXE have been identified. The following is derived from MXE/NMDAR-antagonist class guidance and first principles.

**Critical risks to communicate:**
1. **Potency:** HXE has a lower NMDAR IC₅₀ (0.227 µM) than MXE (0.524 µM); users familiar with MXE doses should expect HXE to be **approximately 2× more potent** at the NMDAR (Irie et al. 2022 [Ref 1]). ⚑ SAFETY-CRITICAL.
2. **Polydrug risk:** The fatal MXE+amphetamine case (Wiergowski et al. 2014 [Ref 25]) demonstrates extreme risk from combining NMDAR antagonists with stimulants (hyperthermia, rhabdomyolysis, multi-organ failure).
3. **CNS depression:** Combination with CNS depressants (alcohol, benzodiazepines, opioids) compounds sedation and respiratory depression risk.
4. **MAOI interaction:** NMDAR antagonists may have serotonergic activity (via SERT); combination with MAOIs poses serotonin syndrome risk. No published HXE-specific data; class-level warning.
5. **Testing:** HXE would not be detected by standard immunoassay drug panels designed for PCP/ketamine (Mohr et al. 2022 [Ref 16]; Luethi & Liechti 2020 [Ref 9]). Forensic LC-MS/MS methods exist for related compounds (Pelixo et al. 2024 [Ref 29]).
6. **Dose sensitivity:** Starting doses should be conservative given HXE's superior NMDAR potency vs. MXE.

**Contraindications (class-level):**
- Hepatic or renal impairment (MXE has caused rhabdomyolysis and multi-organ failure)
- Bladder/urological conditions (ketamine-class compounds cause chronic urothelial damage)
- Personal or family history of psychosis (NMDAR antagonists are psychotomimetic)
- Concurrent MAOI use
- Cardiovascular disease (ketamine-class compounds elevate heart rate and blood pressure)

---

## Tolerance & Dependence

No published tolerance or dependence data specific to HXE has been identified. The seed data values (tolerance buildup with prolonged use; half-life 5 days; full reset 1.5 weeks; cross-tolerances: dissociative; physical dependence: moderate; psychological dependence: moderate) are not sourced from published HXE literature.

**Class-level context:**
- Ketamine dependence has been documented clinically (Pal et al. 2002 [Ref — not separately cited]), with tolerance development without prominent withdrawal at typical use levels
- NMDAR antagonist class drugs produce functional tolerance at the receptor level
- Cross-tolerance within the dissociative class (ketamine, MXE, PCP, and analogs) is expected pharmacologically from shared NMDAR mechanism
- Botanas et al. (2019 [Ref 13]) reviewed preclinical evidence that MXE has abuse liability via mesolimbic dopamine stimulation

⚑ FLAG: The specific tolerance half-life (5 days) and reset time (1.5 weeks) in seed data are not verified against any published source for HXE or for the arylcyclohexylamine class. These values may have been inferred from ketamine or community consensus. Review recommended.

---

## Interactions

No published drug interaction studies for HXE have been identified. The following is class-level inference from MXE and ketamine data.

| Interaction | Risk level | Mechanism | Source basis |
|---|---|---|---|
| Stimulants (amphetamine, cocaine, MDMA) | SEVERE | Hyperthermia, rhabdomyolysis, cardiac stress | Wiergowski 2014 [Ref 25] — fatal case |
| CNS depressants (alcohol, benzos, opioids) | HIGH | Additive CNS/respiratory depression, sedation | Class-level inference |
| MAOIs | HIGH | Potential serotonin syndrome (SERT activity of MXE/HXE class) | Roth 2013 [Ref 5]; Marti 2021 [Ref 14] |
| Other NMDAR antagonists (ketamine, DCK, DXM) | HIGH | Additive dissociation, unpredictable potentiation | Pharmacological class |
| Tramadol | MODERATE | Combined serotonergic + seizure threshold lowering | Class-level |
| Lithium | MODERATE | May lower seizure threshold | Class-level |

⚑ FLAG: All interaction severity ratings are class-level inferences, not HXE-specific published data. The stimulant interaction is the most strongly evidenced (via fatal MXE case). All others require expert editorial review.

---

## Legal Status

### United States
HXE was **not explicitly listed as a federal Schedule I/II controlled substance** as of the CFSRE report dated August 31, 2022 [Ref 17]. HXE may fall under the **Federal Analogue Act** (21 U.S.C. § 813) as a substance "substantially similar" to ketamine (Schedule III) or to MXE, which was placed in **Schedule I effective July 6, 2022** (DEA final rule, Federal Register 2022 [Ref 26]).

⚑ FLAG/DISCREPANCY: The CFSRE August 2022 report states "neither hydroxetamine nor methoxetamine are explicitly scheduled substances under U.S. federal law" — but MXE was placed in Schedule I on July 6, 2022. This suggests either the CFSRE text predates the final scheduling, or an error in the report. HXE's US status remains "not explicitly scheduled" as a standalone substance; its analog status under the FAA is a legal question, not a pharmacological one.

### United Kingdom
HXE almost certainly falls under the UK Misuse of Drugs Act 1971 as a **Class B drug** under the generic arylcyclohexylamine catch-all definition enacted following the ACMD's 2012/2013 review of MXE (GOV.UK / ACMD 2013 [Ref 27]). The definition covers:

> "1-Phenylcyclohexylamine or any compound structurally derived from 1-phenylcyclohexylamine or **2-amino-2-phenylcyclohexanone** by modification through **substitution at the nitrogen atom**, **substitution in the phenyl ring**, substitution in the cyclohexyl or cyclohexanone ring, or replacement of the phenyl ring with a thienyl ring."

HXE = 2-(ethylamino)-2-(3-hydroxyphenyl)cyclohexan-1-one is derived from 2-amino-2-phenylcyclohexanone by N-substitution (ethyl) and phenyl ring substitution (3-OH), fitting this definition.

Additionally, HXE is subject to the **Psychoactive Substances Act 2016**, which prohibits supply of any psychoactive substance in the UK.

⚑ FLAG: The specific applicability of the MDA catch-all to HXE should be confirmed by a UK legal expert; this is a research assessment, not legal advice.

### France
MXE was classified as a controlled substance (*stupéfiant*) in France in **August 2013** (Erowid / Imbert et al. 2014). HXE, as a structural derivative, may be covered under French analog provisions. The 2026 addictovigilance study (Mezaache et al. [Ref 2]) covers ketamine analogue NPS in France, suggesting active monitoring.

### Germany
MXE was controlled in Germany in **July 2013**. Germany's NpSG (Neue-psychoaktive-Stoffe-Gesetz, 2016) bans all NPS; HXE almost certainly covered.

### Netherlands
MXE placed on List 1 of Opium Law in **July 2015**. HXE status unclear but NPS legislation likely applies.

### Canada
MXE is classified as Schedule I (January 2011). HXE was identified in at least one Canadian toxicology case since **November 2021** (CFSRE 2022 [Ref 17]). Whether HXE is explicitly scheduled in Canada was not determined from available sources.

### Australia
No specific scheduling information for HXE was identified in Australian TGA/SUSMP sources. Class-level controls may apply via ketamine analog provisions.

---

## Clinical Trials

No clinical trials involving HXE were found on ClinicalTrials.gov or in the published literature. As an unscheduled or ambiguously scheduled research chemical with no approved medical use, clinical development is not currently active.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Safety-Critical Values Not Verified Against Published Sources
1. ⚑ **All dose ranges in the seed data** (oral, sublingual, insufflated) are not sourced from any published clinical study. They are drawn from community consensus (PsychonautWiki data generally consistent). Mark as "community_consensus" provenance.
2. ⚑ **Duration data** in seed data is similarly unverified against published studies. Community reports are broadly consistent with MXE's longer-than-ketamine duration.
3. ⚑ **Tolerance half-life (5 days) and full reset (1.5 weeks)**: Not found in any published source. Should be flagged as inferred/community data.
4. ⚑ **"Linked to adverse events including deaths"** per CFSRE: No peer-reviewed HXE-specific death case report found. Human editorial review of CFSRE raw data recommended.
5. ⚑ **HXE NMDAR IC₅₀ is ~2× more potent than MXE**: This has direct dosing safety implications. If users are applying MXE dosing intuitions to HXE, they may over-dose significantly. This should be prominently stated in any published article.

### Data Gaps
- No published human pharmacokinetic data for HXE as a standalone substance
- No published HXE-specific mu-opioid receptor or sigma receptor binding data (Ki, EC₅₀)
- No published stereochemistry data — HXE has a chiral center at C-2 of the cyclohexanone ring; sold as racemate presumed but unconfirmed
- No published melting point, water solubility, or stability data for HXE
- No case reports of chronic HXE use and bladder/organ toxicity
- No clinical trials; no human volunteer studies

### Source Contradictions
- ⚑ CFSRE August 2022 report states "neither hydroxetamine nor methoxetamine are explicitly scheduled substances under U.S. federal law" — this contradicts the DEA final rule placing MXE in Schedule I effective July 6, 2022 [Ref 26]. The CFSRE statement may have been written before the final scheduling effective date or may be a documentation error. HXE's federal US status is "not explicitly scheduled as of research date."
- ⚑ Seed data pharmacological class includes "Mu-opioid receptor agonist" and "Sigma receptor agonist" — these are class-level inferences not confirmed by HXE-specific published binding data. Roth et al. (2013 [Ref 5]) found sigma activity was more prominent in non-β-keto PCP analogs than in MXE.

### Analogy-Dependent Sections
The following sections rely substantially or entirely on structural analogy to MXE/ketamine rather than HXE-specific data:
- Mu-opioid receptor activity
- Sigma receptor activity
- SERT activity and serotonergic effects
- Bladder/organ toxicity risks
- Drug interaction severity ratings
- Tolerance and dependence magnitude estimates
- Psychological risk characterization

These should be explicitly caveated in article prose as class-inferred or MXE-analogized.